{"gene":"ATP2A2","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1988,"finding":"Molecular cloning of human kidney cDNAs revealed that the cardiac Ca2+-ATPase (ATP2A2/SERCA2) gene produces two alternatively spliced products: SERCA2a (identical to cardiac muscle Ca2+-ATPase) and SERCA2b (with the carboxyl-terminal 4 amino acids replaced by an extended 49-amino-acid sequence), with SERCA2b being the most abundant isoform in non-muscle tissues.","method":"cDNA cloning, Southern blotting, sequencing, and immunological characterization of microsomal fractions","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with structural validation; foundational paper with 332 citations","pmids":["2844796"],"is_preprint":false},{"year":1990,"finding":"Co-expression of SERCA2 with phospholamban in COS-1 cells demonstrated that phospholamban directly inhibits SERCA2 by lowering its Ca2+ affinity, establishing functional interaction between the two proteins.","method":"Transient transfection of COS-1 cells, Ca2+-transport assays in microsomes","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — reconstituted functional interaction in heterologous expression system; replicated across multiple subsequent studies","pmids":["2146166"],"is_preprint":false},{"year":1997,"finding":"The relative ratio of phospholamban to SERCA2 is a critical determinant of myocardial contractility; atrial muscles with a 4.2-fold lower phospholamban:SERCA2 ratio exhibit threefold faster contraction/relaxation rates than ventricular muscles, and phospholamban knockout hearts show enhanced contractility, demonstrating that phospholamban:SERCA2 stoichiometry directly regulates pump-dependent Ca2+ handling.","method":"Comparison of atrial vs. ventricular contractile parameters; phospholamban knockout mouse hearts; isolated work-performing heart preparations","journal":"Basic research in cardiology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout + functional cardiac measurements; replicated across two experimental comparisons","pmids":["9202840"],"is_preprint":false},{"year":1999,"finding":"Loss-of-function mutations in ATP2A2 (encoding SERCA2) cause Darier disease, demonstrating that SERCA2-mediated Ca2+ signaling is essential for keratinocyte cell-to-cell adhesion and differentiation. Thirteen mutations including frameshift deletions, splice-site mutations, and missense mutations in functional domains were identified.","method":"Mutation screening of ATP2A2 in Darier disease families; identification of 13 mutations in functional domains","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with defined cellular phenotype (acantholysis, abnormal keratinization); foundational paper with 576 citations","pmids":["10080178"],"is_preprint":false},{"year":1999,"finding":"Heterozygous null mutation in the SERCA2 gene reduces SERCA2 mRNA by ~45%, protein and maximal Ca2+ uptake velocity by ~35%, and impairs cardiac contractility and relaxation, demonstrating that two functional copies of SERCA2 are required for normal cardiac Ca2+ sequestration and function.","method":"Gene targeting in mice; RNase protection, Western blotting, biochemical Ca2+ uptake assays, in vivo cardiovascular pressure measurements","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — genetic knockout with multiple orthogonal biochemical and functional measurements; 213 citations","pmids":["9891028"],"is_preprint":false},{"year":1999,"finding":"Gene transfer of SERCA2a into failing human cardiomyocytes restores pump activity, increases contraction and relaxation velocity, decreases diastolic Ca2+, increases systolic Ca2+, and normalizes the frequency response, establishing that SERCA2a deficiency directly underlies contractile dysfunction in heart failure.","method":"Adenoviral gene transfer into isolated human failing cardiomyocytes; Ca2+ imaging, contractility measurements","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1-2 — direct gain-of-function rescue experiment in human cells with functional readouts; 386 citations","pmids":["10587333"],"is_preprint":false},{"year":2000,"finding":"Disruption of one SERCA2 allele in mice reduces SR Ca2+ stores and Ca2+ release by ~30–60%, decreases myocyte shortening/relengthening rates by ~40%, and triggers compensatory reductions in phospholamban (by ~40%) with increased basal phosphorylation of PLB at Ser-16 and Thr-17 (~2-fold), along with upregulation of the Na+-Ca2+ exchanger, revealing adaptive mechanisms that partially compensate for reduced SERCA2 levels.","method":"SERCA2 heterozygous knockout mice; confocal Ca2+ imaging, myocyte contractility measurements, Western blotting, electrophysiology","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic model with multiple orthogonal functional and biochemical readouts; 107 citations","pmids":["10970890"],"is_preprint":false},{"year":2000,"finding":"Somatic (mosaic) mutations in ATP2A2 cause segmental Darier disease following Blaschko's lines, confirming that postzygotic ATP2A2 mutations restricted to affected skin are sufficient to produce acantholytic dyskeratosis.","method":"Mutation analysis of affected skin vs. unaffected skin and leukocytes; identification of nonsense (Y894X) and missense (G769R) mutations present only in affected tissue","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 — direct genotype-tissue comparison establishing somatic mosaicism; 108 citations","pmids":["11121153"],"is_preprint":false},{"year":2001,"finding":"Haploinsufficiency of Atp2a2 (SERCA2) predisposes mice to squamous cell tumors of the forestomach, esophagus, oral mucosa, tongue, and skin, with 13/14 heterozygous mice developing tumors versus none in wild-type controls, establishing that perturbation of Ca2+ homeostasis via SERCA2 reduction can serve as a primary initiating event in squamous cell carcinogenesis.","method":"Aged Atp2a2+/- mice; histopathology, Western blot analysis of SERCA2 in affected tissues","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic model with clear tumor phenotype and molecular confirmation; 91 citations","pmids":["11389134"],"is_preprint":false},{"year":2001,"finding":"In SERCA2+/- mice, the shorter Ca2+ transient evoked by agonist stimulation is due to upregulation of specific plasma membrane Ca2+ pump isoforms; Ca2+ oscillation frequency is reduced ~50%, but agonist-stimulated exocytosis is preserved through compensatory increases in Ca2+ sensitivity of exocytosis mediated by altered levels of Ca2+ sensors synaptotagmins I and III.","method":"SERCA2+/- mouse model; Ca2+ imaging, exocytosis assays, Western blotting of synaptotagmin isoforms","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — genetic model with multiple orthogonal functional assays revealing specific adaptive mechanisms; 60 citations","pmids":["11387203"],"is_preprint":false},{"year":2004,"finding":"S-Glutathiolation of SERCA2 at Cys674 by NO-derived peroxynitrite directly activates SERCA Ca2+-uptake activity and mediates arterial relaxation; mutation of Cys674 to serine abolishes this activation, and irreversible oxidation of Cys674 to sulfonic acid in atherosclerosis prevents NO-dependent SERCA activation and arterial relaxation.","method":"Purified SERCA reconstituted in phospholipid vesicles; site-directed mutagenesis (C674S); Ca2+-uptake assays; mass spectrometry of oxidized Cys674 in atherosclerotic tissue","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1 — reconstitution + mutagenesis + disease tissue validation; 541 citations","pmids":["15489859"],"is_preprint":false},{"year":2005,"finding":"Atp2a2 haploinsufficiency causes squamous cell tumorigenesis via a novel mechanism not involving loss of heterozygosity (wild-type allele retained in tumors), without ras mutations, but with upregulated K-ras expression, establishing a cancer susceptibility mode based on global change in tumorigenic potential of keratinized epithelium.","method":"Laser capture microdissection of tumor cells; PCR for wild-type allele; ras mutation analysis; immunohistochemistry; Western blot; p53 analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — molecular dissection of tumor mechanism in genetic model with multiple analyses; 59 citations","pmids":["16204033"],"is_preprint":false},{"year":2008,"finding":"Calumenin, a multiple EF-hand Ca2+-binding protein located in the cardiac SR lumen, directly interacts with SERCA2 and inhibits SERCA2-mediated Ca2+ uptake; the interaction is favored in the E1 state of SERCA2, and the binding regions are residues 132-222 of calumenin and 853-892 of SERCA2 luminal loop L4.","method":"Co-immunoprecipitation; GST-pulldown with calumenin deletion fragments and SERCA2 luminal domains; oxalate-supported Ca2+ uptake assays; calumenin knockdown in HL-1 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding domain mapping by GST-pulldown + functional Ca2+ uptake assays + cellular knockdown; 52 citations","pmids":["19740751"],"is_preprint":false},{"year":2010,"finding":"Mitochondrial transcription factors TFAM and TFB2M bind to the -122 to -114 nt region of the Serca2 gene promoter in rat neonatal cardiomyocytes (demonstrated by ChIP and fluorescence correlation spectroscopy), and their overexpression prevents stress-induced decreases in SERCA2a mRNA, revealing that these factors coordinate transcription of both mitochondrial metabolic genes and the SERCA2 gene.","method":"Chromatin immunoprecipitation (ChIP); fluorescence correlation spectroscopy; promoter mutation analysis; adenoviral overexpression; rat myocardial infarction model","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — direct promoter binding demonstrated by ChIP + mutagenesis + in vivo correlation; 45 citations","pmids":["21113058"],"is_preprint":false},{"year":2011,"finding":"SERCA2a is SUMOylated at lysines 480 and 585, and this SUMOylation is essential for maintaining SERCA2a ATPase activity and stability; SUMO1 levels and SERCA2a SUMOylation are reduced in failing hearts, and AAV-mediated SUMO1 restoration improves SERCA2a function and cardiac performance comparably to SERCA2a gene delivery.","method":"Site-directed mutagenesis of K480 and K585; adeno-associated virus gene delivery; in vitro ATPase assays; cardiomyocyte Ca2+ decay measurements; pressure-overload mouse model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis identifying specific SUMOylation sites + in vivo rescue experiments; 320 citations","pmids":["21900893"],"is_preprint":false},{"year":2011,"finding":"SERCA2 protein aggregation is triggered by Darier disease-associated missense mutations; these mutant proteins are less soluble, aggregate, become polyubiquitinated, and when transduced into primary keratinocytes, elicit ER stress and induce apoptosis and cell detachment, establishing a gain-of-toxic-function pathogenic mechanism distinct from simple haploinsufficiency.","method":"Expression of DD-associated SERCA2 mutants; solubility assays; polyubiquitination assays; adenoviral transduction into primary human keratinocytes; ER stress markers; apoptosis assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 — systematic analysis of multiple DD mutants with orthogonal biochemical and cellular readouts; 33 citations","pmids":["22045735"],"is_preprint":false},{"year":2012,"finding":"SERCA2b-controlled ER Ca2+ sequestration regulates keratinocyte adhesion and differentiation via the sphingolipid signaling pathway: SERCA2b inhibition increases sphingosine levels and decreases sphingosine kinase (SPHK1) expression, and inhibiting sphingolipid lyase rescues defects in keratinocyte differentiation, E-cadherin localization, and desmoplakin translocation caused by SERCA2 inhibition.","method":"SERCA2b inhibition with thapsigargin and siRNA; sphingolipid pathway analysis; rescue experiments with sphingolipid lyase inhibitor; immunofluorescence of E-cadherin and desmoplakin","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 — pathway epistasis established by pharmacological and genetic perturbations with specific molecular readouts; 34 citations","pmids":["22277942"],"is_preprint":false},{"year":2015,"finding":"Phosphodiesterase 3A1 (PDE3A1) directly interacts with SERCA2 in human cardiac SR; phosphorylation of PDE3A1 by PKA at Ser-292/Ser-293 (unique to PDE3A1) promotes its incorporation into SERCA2/AKAP18 signalosomes; PDE3A co-immunoprecipitates with SERCA2, cav3, PKARII, PP2A, and AKAP18; and deletion of the PDE3A1 N-terminus blocks SERCA2 interaction, placing PDE3A1 as a regulator of a discrete cAMP pool controlling PLB phosphorylation and SERCA2 activity.","method":"Co-immunoprecipitation of endogenous proteins from human SR; gel filtration chromatography; recombinant protein co-IP; deletion mutants; site-directed mutagenesis; PKA phosphorylation assays; immunohistochemistry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal co-IP + mutagenesis + recombinant protein interaction mapping + functional assays; 83 citations","pmids":["25593322"],"is_preprint":false},{"year":2016,"finding":"SERCA2 deficiency in pancreatic beta cells impairs ER Ca2+ homeostasis, glucose-induced Ca2+ mobilization, insulin secretion, proinsulin processing, and beta-cell mass under high-fat diet conditions; pharmacological SERCA2 activation rescues tunicamycin-induced beta-cell death, establishing SERCA2 as critical for the beta-cell compensatory response to obesity.","method":"SERCA2 heterozygous mice on high-fat diet; Ca2+ imaging in islets; insulin secretion assays; beta-cell mass quantification; ER stress markers; SERCA2 activator treatment","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — genetic model + pharmacological rescue with multiple functional readouts; 74 citations","pmids":["27489309"],"is_preprint":false},{"year":2020,"finding":"JNK2 (but not JNK1) directly associates with and phosphorylates SERCA2, increasing SERCA2 ATPase activity (maximal rate without altering Ca2+ affinity) and SR Ca2+ content in a CaMKII-independent manner, thereby exacerbating an arrhythmic SR Ca2+ leak-load relationship in aged and alcohol-exposed hearts.","method":"Confocal Ca2+ imaging; biochemical SERCA2 ATPase activity assays; co-immunoprecipitation; dual Ca2+/voltage optical mapping in intact hearts; JNK2-specific inhibition; CaMKII inhibitor controls","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 — direct biochemical phosphorylation + ATPase activity assay + co-IP + functional imaging; 41 citations","pmids":["33334123"],"is_preprint":false},{"year":2020,"finding":"O-GlcNAcylation of SERCA2 in pancreatic beta cells, mediated by OGT, is required for lipid-stimulated insulin hypersecretion; SERCA2 was identified as a beta-cell O-GlcNAcylated protein in mice and humans, and pharmacological SERCA2 activation rescues impaired palmitate-stimulated insulin secretion in OGT-deficient islets.","method":"OGT-specific beta-cell knockout mice; in vivo and in vitro insulin secretion assays; identification of O-GlcNAcylated SERCA2 by proteomic approaches; pharmacological SERCA2 activation","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — genetic model + pharmacological rescue; O-GlcNAcylation of SERCA2 identified but specific sites not mapped by mutagenesis","pmids":["32375037"],"is_preprint":false},{"year":2020,"finding":"TG2-mediated serotonylation of SERCA2 inhibits SERCA2 activity, leading to increased cytosolic Ca2+ and store-operated Ca2+ entry via TRPC6; hypoxia enhances TG2 expression and activity promoting SERCA2 serotonylation both in vitro and in vivo, and vascular smooth muscle-specific Tgm2 knockout prevents hypoxia-induced pulmonary vascular remodeling.","method":"Co-immunoprecipitation; TG2 gene silencing/overexpression; SERCA2 activity assays; Fluo-4AM Ca2+ measurements; tissue-specific conditional TG2 knockout mice; hemodynamic measurements","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP + functional assays + genetic model; serotonylation site not confirmed by mutagenesis","pmids":["32116663"],"is_preprint":false},{"year":2020,"finding":"Inactivation of SERCA2 Cys674 (C674S knock-in, representing irreversible oxidation) causes intracellular Ca2+ accumulation that activates calcineurin, promoting nuclear translocation of NFAT and NF-κB, resulting in smooth muscle cell phenotypic modulation and acceleration of angiotensin II-induced aortic aneurysm.","method":"SERCA2 C674S heterozygous knock-in mice; aortic aneurysm model; calcineurin inhibition; NFAT/NFκB nuclear translocation assays; SMC phenotypic marker Western blots","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 — knock-in mouse model with defined molecular mechanism and pathway placement; 21 citations","pmids":["32035136"],"is_preprint":false},{"year":2020,"finding":"Inactivation of SERCA2 Cys674 in the kidney (C674S knock-in mice) promotes hypertension by inducing ER stress and upregulating soluble epoxide hydrolase (sEH), which together suppress dopamine D1 receptor expression, impairing Na+/K+-ATPase regulation and sodium excretion.","method":"SERCA2 C674S heterozygous knock-in mice; blood pressure measurement; urine sodium/volume analysis; ER stress marker Western blots; D1 receptor expression; Na+/K+-ATPase activity assays","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knock-in model with pathway inhibitor experiments establishing mechanism; single study","pmids":["31758704"],"is_preprint":false},{"year":2021,"finding":"AKAP18δ anchors CaMKIIδ at SERCA2-PLN and RYR via two distinct regions: an N-terminal region (AKAP18δ-N) inhibits CaMKIIδ by binding a region homologous to CaMKII inhibitor peptide and the Thr17-PLN region, while a C-terminal region (AKAP18δ-C) activates CaMKIIδ by lowering the Ca2+ threshold for kinase activation and inducing CaM trapping; AKAP18δ-C facilitates faster Ca2+ reuptake by SERCA2.","method":"Peptide arrays; cell-permeant peptide technology; immunoprecipitations; pull-downs; FRET-based CaMKII activity assays; SR vesicle fluorescence imaging; surface plasmon resonance; AAV injection in mice","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including SPR, FRET, peptide mapping, and in vivo validation; 40 citations","pmids":["34814703"],"is_preprint":false},{"year":2021,"finding":"Brain-specific heterozygous loss of Atp2a2 (SERCA2) in mice causes slower cytosolic Ca2+ decay after neuronal depolarization (due to decreased ER Ca2+ uptake), behavioral abnormalities including altered novelty responses and impaired fear memory, and elevated extracellular dopamine in the nucleus accumbens, establishing that SERCA2 haploinsufficiency in brain produces a hyperdopaminergic state.","method":"Brain-specific conditional Atp2a2 heterozygous knockout mice; ER Ca2+ uptake assays; neuronal Ca2+ imaging after depolarization; behavioral testing; in vivo microdialysis for dopamine","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — conditional genetic model with biochemical, Ca2+ imaging, behavioral, and in vivo neurochemical readouts; 25 citations","pmids":["34104969"],"is_preprint":false},{"year":2022,"finding":"Sigma-1 receptor (Sigmar1) interacts with SERCA2 (with Q615 as the critical binding residue) and promotes SERCA2 degradation through Hrd1/Sel1L-dependent ER-associated degradation (ERAD), with ubiquitination of SERCA2 at K460 and K541 targeting it for proteasomal degradation; this mechanism attenuates osteoclastogenesis.","method":"IP-mass spectrometry; co-immunoprecipitation; mutagenesis of SERCA2 Q615 and K460/K541; ERAD inhibition; proteasome inhibitor experiments; Sigmar1 knockout and overexpression in mice","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 1-2 — IP-MS + co-IP + mutagenesis identifying specific interaction and ubiquitination sites + genetic models; 31 citations","pmids":["35611810"],"is_preprint":false},{"year":2022,"finding":"SERCA2 oxidation and inactivation by xanthine oxidase (XO) during cardiac ischemia/reperfusion leads to cytoplasmic Ca2+ overload, CaMKII activation, and cofilin phosphorylation causing F-actin depolymerization and endothelial dysfunction; SGLT2 inhibitor dapagliflozin inhibits this XO-SERCA2-CaMKII-cofilin pathway, and its protective effects are lost in SERCA2-knockout mice.","method":"SERCA2 knockout mice subjected to ischemia/reperfusion; human coronary artery endothelial cells with hypoxia/reoxygenation; XO activity measurements; SERCA2 oxidation assays; CaMKII and cofilin phosphorylation; endothelial function assays","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout validation + pathway dissection with multiple orthogonal assays in vivo and in vitro; 99 citations","pmids":["35836807"],"is_preprint":false},{"year":2022,"finding":"SERCA2 interacts with LC3B via an LIR motif to facilitate WIPI2-independent autophagosome formation, promoting autophagy in triple-negative breast cancer cells; autophagy-mediated SERCA2 degradation induces SERCA2 transcriptional upregulation through a Ca2+/CaMKK/CREB-1 feedback loop.","method":"Co-immunoprecipitation of SERCA2 with LC3B; LIR motif identification; autophagy flux assays; Ca2+ imaging; CaMKK inhibition; CREB-1 reporter assays; in vitro and in vivo tumor models","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP + pathway inhibition experiments; mechanistic details of LIR-mediated interaction need structural confirmation","pmids":["36561988"],"is_preprint":false},{"year":2023,"finding":"SERCA2 phosphorylation at serine 663 is increased in ischemic human and mouse hearts; preventing serine 663 phosphorylation significantly increases SERCA2 activity and protects against cell death by counteracting cytosolic and mitochondrial Ca2+ overload, establishing serine 663 as a pathophysiological regulatory site of SERCA2 activity.","method":"Phosphoproteomic analysis of ischemic human hearts; mutagenesis preventing S663 phosphorylation; SERCA2 ATPase activity assays; Ca2+ homeostasis measurements in human cell lines; infarct size analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — clinical tissue validation + mutagenesis + functional enzyme assays; 32 citations","pmids":["37291092"],"is_preprint":false},{"year":2023,"finding":"MFN2 interacts with ER-embedded SERCA2 at mitochondria-ER contact sites (MAMs) to enhance SERCA2 ER Ca2+ retrieval activity, facilitating mitochondrial Ca2+ influx required for efficient mitochondrial metabolism in CD8+ T cells while preventing excessive mitochondrial Ca2+ accumulation and apoptosis.","method":"Co-immunoprecipitation of MFN2 and SERCA2; Mfn2 genetic ablation in CD8+ T cells; mitochondria-ER contact site imaging; mitochondrial Ca2+ measurements; metabolic assays; tumor models","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 — co-IP establishing direct interaction + genetic ablation + functional metabolic readouts; 75 citations","pmids":["37738362"],"is_preprint":false},{"year":2023,"finding":"SERCA2 deficiency in beta cells impairs spatial regulation of prohormone trafficking, causing mis-location of proinsulin and proPC2 to the ERGIC/cis-Golgi, and decreases expression of active forms of proinsulin processing enzymes PC1/3 and PC2, linking ER Ca2+ depletion to defective insulin maturation.","method":"Beta-cell-specific SERCA2 knockout mice; RNA-seq; Ca2+ imaging; proinsulin processing assays; immunofluorescence of proinsulin and proPC2 localization; INS-1 SERCA2-deficient cell line","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 — conditional beta-cell knockout with detailed mechanistic analysis of processing enzyme localization and activity; 15 citations","pmids":["37537395"],"is_preprint":false},{"year":2023,"finding":"PDE3A directly binds to amino acids 169-216 within the actuator domain of SERCA2 via PDE3A amino acids 277-402, and this interaction inhibits SERCA2 activity independently of PDE3A catalytic activity; disruption of the SERCA2/PDE3A interaction by disruptor peptides increases SERCA2 activity in normal and failing cardiomyocytes and reduces cardiac mortality after aortic banding in mice.","method":"2-color dSTORM; proximity ligation assay; co-immunoprecipitation; peptide arrays; surface plasmon resonance; HEK293 vesicle Ca2+ uptake assays; AAV9 gene delivery in mice; serial echocardiography; cardiac MRI","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding domain mapping by multiple methods + functional ATPase assays + in vivo preclinical trials; 19 citations","pmids":["36876489"],"is_preprint":false},{"year":1998,"finding":"An E box/AT-rich element at -1115 bp is critical for muscle-specific enhancer activity of the SERCA2 gene promoter; gel mobility shift studies show this element specifically binds a protein induced during myogenesis, and it acts together with CArG and MCAT elements to regulate SERCA2 transcription.","method":"Deletion analysis; reporter gene assays in Sol8 myotubes; gel mobility shift assays; mutagenesis of cis-acting elements","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — deletion analysis + EMSA + mutagenesis; specific transcription factor identity not fully established","pmids":["9461473"],"is_preprint":false},{"year":1996,"finding":"The human SERCA2 gene promoter contains a TATA-like box, CAAT-box, three Sp1 sites, a CACCC-box, OTF-1 binding sequence, and two putative thyroid response elements; sequences from -263 to +170 bp are necessary for maximal transcriptional activity and sequences from -125 to +170 bp are essential for basal activity in cardiomyocytes and myotubes.","method":"Genomic cloning; 5' deletion reporter constructs; transfection into neonatal rat cardiomyocytes and C2C12 myotubes; luciferase assays","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — systematic promoter deletion analysis with functional reporter assays; 21 citations","pmids":["8930809"],"is_preprint":false},{"year":2021,"finding":"Cardiac troponin I (cTnI) translocates to the nucleus in cardiomyocytes and binds to the Atp2a2 promoter in the -239 to -889 region at a 'CCAT' motif, positively regulating SERCA2a expression; TNNI3 gain/loss causes dose-dependent Atp2a2 mRNA and protein changes, and increasing cTnI increases SERCA2a promoter activity in luciferase assays.","method":"ChIP-sequencing; luciferase reporter assays; TNNI3 siRNA and overexpression; Western blotting; Ca2+ transient measurements","journal":"Genes & diseases","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq + luciferase reporter + gene manipulation; single study with moderate functional follow-up","pmids":["36157491"],"is_preprint":false},{"year":2022,"finding":"Substitution of SERCA2 Cys674 (C674S knock-in) activates the IRE1α/XBP1s ER stress pathway in pulmonary artery smooth muscle cells, accelerating cell cycle and proliferation, leading to pulmonary vascular remodeling resembling pulmonary hypertension; this is reversed by IRE1α/XBP1s pathway inhibitor 4μ8C.","method":"SERCA2 C674S heterozygous knock-in mice; IRE1α/XBP1s pathway analysis; cell cycle assays; PASMC proliferation assays; right ventricular systolic pressure measurements","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knock-in + pathway inhibitor rescue; mechanistic link between C674 oxidation and IRE1α activation not fully biochemically established","pmids":["35646520"],"is_preprint":false}],"current_model":"ATP2A2 (SERCA2) encodes a P-type Ca2+-ATPase that pumps cytosolic Ca2+ into the SR/ER lumen; its two major isoforms (SERCA2a in cardiac/slow-twitch muscle, SERCA2b ubiquitously expressed) are regulated by multiple direct protein interactions and post-translational modifications including: inhibition by phospholamban (relieved by PLB phosphorylation), activation by S-glutathiolation at Cys674 by NO/peroxynitrite, SUMOylation at Lys480/Lys585 that maintains ATPase stability and activity, phosphorylation at Ser663 (inhibitory) and by JNK2 (activating), O-GlcNAcylation, serotonylation by TG2 (inhibitory), and inhibitory binding by calumenin and PDE3A1 (whose phosphorylation at Ser292/293 by PKA promotes its incorporation into a SERCA2/AKAP18 signalosome); SERCA2 activity is anchored and regulated at the SR by AKAP18δ-CaMKIIδ complexes, and its transcription is controlled by NFAT/calcineurin, TFAM/TFB2M, ERK/NF-κB, and cTnI; haploinsufficiency causes Darier disease (acantholysis and dyskeratosis), squamous cell tumors, and a hyperdopaminergic neuropsychiatric phenotype, while SERCA2 reduction in failing hearts impairs Ca2+ homeostasis and contractility, establishing it as a central regulator of Ca2+ cycling in multiple cell types."},"narrative":{"teleology":[{"year":1988,"claim":"Molecular cloning established that a single ATP2A2 gene produces two isoforms—cardiac SERCA2a and ubiquitous SERCA2b—through alternative splicing, resolving the molecular basis of tissue-specific Ca²⁺ pump expression.","evidence":"cDNA cloning and sequencing of human kidney SERCA2 transcripts with Southern blot and immunological validation","pmids":["2844796"],"confidence":"High","gaps":["Functional differences between SERCA2a and SERCA2b catalytic properties not yet compared","Regulatory elements governing isoform-specific splicing unknown"]},{"year":1990,"claim":"Co-expression experiments demonstrated that phospholamban directly inhibits SERCA2 by lowering Ca²⁺ affinity, establishing the first regulatory partner of the pump and the principle that SERCA2 activity is modulated by protein–protein interaction.","evidence":"COS-1 cell co-transfection with Ca²⁺-transport assays in microsomes","pmids":["2146166"],"confidence":"High","gaps":["Structural basis of PLB–SERCA2 interaction unknown","Whether the PLB:SERCA2 stoichiometry has physiological consequences untested"]},{"year":1997,"claim":"The physiological significance of PLB:SERCA2 stoichiometry was demonstrated by showing that chambers with lower PLB:SERCA2 ratios contract faster, and PLB knockout enhances contractility, proving that this ratio is a primary determinant of cardiac Ca²⁺ handling kinetics.","evidence":"Comparison of atrial vs. ventricular contractile parameters and PLB knockout mouse hearts","pmids":["9202840"],"confidence":"High","gaps":["Whether stoichiometric regulation is dynamic under stress conditions unclear","Other endogenous SERCA2 inhibitors not yet identified"]},{"year":1999,"claim":"Three convergent studies established SERCA2 as essential in vivo: loss-of-function mutations caused Darier disease in humans, heterozygous knockout impaired cardiac function in mice, and SERCA2a gene transfer rescued contractile dysfunction in failing human cardiomyocytes, linking pump deficiency to skin, cardiac, and disease phenotypes.","evidence":"Human mutation screening in Darier families; SERCA2+/− mouse cardiovascular measurements; adenoviral SERCA2a delivery to failing human cardiomyocytes with Ca²⁺ and contractility readouts","pmids":["10080178","9891028","10587333"],"confidence":"High","gaps":["Molecular mechanism linking ER Ca²⁺ depletion to keratinocyte acantholysis unknown","Whether all Darier mutations act through haploinsufficiency vs. toxic gain-of-function unresolved"]},{"year":2000,"claim":"Analysis of SERCA2+/− mice revealed compensatory remodeling—upregulation of PMCA isoforms, Na⁺/Ca²⁺ exchanger, and altered PLB phosphorylation—that partially buffers reduced pump activity, establishing the principle that cells adapt Ca²⁺-handling networks when SERCA2 is diminished.","evidence":"SERCA2 heterozygous knockout mice with confocal Ca²⁺ imaging, myocyte contractility, exocytosis assays, and synaptotagmin isoform Western blotting","pmids":["10970890","11387203"],"confidence":"High","gaps":["Whether compensatory mechanisms fail under chronic stress not tested","Mechanisms triggering compensatory gene expression changes unknown"]},{"year":2001,"claim":"SERCA2 haploinsufficiency was found to predispose to squamous cell tumors without loss of heterozygosity, establishing SERCA2 as a haploinsufficient tumor suppressor that alters epithelial tumorigenic potential through Ca²⁺ signaling perturbation.","evidence":"Aged Atp2a2+/− mice with histopathology; laser capture microdissection showing retained wild-type allele; ras mutation and p53 analysis","pmids":["11389134","16204033"],"confidence":"High","gaps":["Downstream oncogenic pathways activated by partial SERCA2 loss not fully defined","Whether tumor suppressor role extends to human epithelial cancers not established"]},{"year":2004,"claim":"Identification of Cys674 S-glutathiolation as a redox-sensitive activating switch resolved how NO signals through SERCA2 to relax arteries, and showed that irreversible Cys674 oxidation in atherosclerosis abolishes this regulation.","evidence":"Reconstituted purified SERCA2 in vesicles; C674S mutagenesis; mass spectrometry of oxidized Cys674 in atherosclerotic tissue","pmids":["15489859"],"confidence":"High","gaps":["Other Cys residues that may undergo regulatory oxidation not surveyed","Whether Cys674 oxidation is reversible in early disease stages unknown"]},{"year":2008,"claim":"Calumenin was identified as a luminal SERCA2 inhibitor that binds the L4 loop (residues 853–892) preferentially in the E1 state, revealing that SERCA2 is regulated from both cytoplasmic and luminal sides.","evidence":"GST-pulldown domain mapping; oxalate-supported Ca²⁺ uptake assays; calumenin knockdown in HL-1 cells","pmids":["19740751"],"confidence":"High","gaps":["Physiological conditions that modulate calumenin–SERCA2 interaction not defined","Whether calumenin and PLB regulation are synergistic or independent unclear"]},{"year":2011,"claim":"Two discoveries expanded the regulatory landscape: SUMOylation at K480/K585 was shown essential for SERCA2a stability and ATPase activity (reduced in heart failure, rescued by SUMO1 gene therapy), and Darier disease missense mutants were found to aggregate, trigger ER stress, and cause apoptosis, revealing a toxic gain-of-function mechanism beyond haploinsufficiency.","evidence":"Site-directed mutagenesis of K480/K585; AAV-SUMO1 delivery in pressure-overload mice; DD mutant expression in keratinocytes with solubility, ubiquitination, and ER stress assays","pmids":["21900893","22045735"],"confidence":"High","gaps":["SUMO E3 ligase responsible for SERCA2a SUMOylation not identified","Which DD mutations act through aggregation vs. pure loss-of-function not systematically classified"]},{"year":2012,"claim":"SERCA2b inhibition was shown to disrupt keratinocyte adhesion through sphingolipid pathway perturbation—increasing sphingosine and decreasing SPHK1—with rescue by sphingolipid lyase inhibition, providing a mechanistic link between ER Ca²⁺ depletion and Darier disease pathology.","evidence":"Thapsigargin and siRNA SERCA2b inhibition; sphingolipid analysis; rescue of E-cadherin and desmoplakin localization by sphingolipid lyase inhibitor","pmids":["22277942"],"confidence":"High","gaps":["Whether sphingolipid pathway is perturbed in Darier patient skin not confirmed","Direct Ca²⁺-sensing mechanism controlling SPHK1 expression unknown"]},{"year":2015,"claim":"PDE3A1 was identified as a SERCA2 signalosome component: PKA-dependent phosphorylation of PDE3A1 at Ser292/293 promotes its incorporation into SERCA2/AKAP18 complexes, establishing a mechanism by which local cAMP pools control PLB phosphorylation and SERCA2 activity.","evidence":"Reciprocal co-IP of endogenous proteins from human SR; deletion mutant and mutagenesis mapping; gel filtration chromatography","pmids":["25593322"],"confidence":"High","gaps":["Whether PDE3A1 directly modulates SERCA2 activity independent of cAMP hydrolysis not tested at this time"]},{"year":2016,"claim":"SERCA2 was established as critical for pancreatic β-cell function: heterozygous loss impaired glucose-stimulated Ca²⁺ mobilization, insulin secretion, and β-cell mass under metabolic stress, and pharmacological SERCA2 activation rescued β-cell death.","evidence":"SERCA2+/− mice on high-fat diet; Ca²⁺ imaging in islets; insulin secretion assays; SERCA2 activator treatment","pmids":["27489309"],"confidence":"High","gaps":["Specific SERCA2 activator mechanism of action not characterized","Whether SERCA2 dysfunction contributes to human type 2 diabetes not directly shown"]},{"year":2020,"claim":"Multiple new regulatory modifications and downstream consequences were uncovered: JNK2 directly phosphorylates SERCA2 to increase Vmax; O-GlcNAcylation modulates β-cell insulin hypersecretion; TG2-mediated serotonylation inhibits SERCA2 promoting pulmonary vascular remodeling; and Cys674 inactivation activates calcineurin/NFAT signaling driving aneurysm and hypertension through ER stress pathways.","evidence":"Co-IP and ATPase assays (JNK2); OGT β-cell knockout with SERCA2 activation rescue; TG2 conditional knockout with hemodynamics; C674S knock-in mice with calcineurin, IRE1α, and renal pathway analyses","pmids":["33334123","32375037","32116663","32035136","31758704"],"confidence":"High","gaps":["JNK2 phosphorylation site on SERCA2 not mapped","O-GlcNAcylation sites not identified by mutagenesis","Serotonylation site not confirmed by mutagenesis"]},{"year":2021,"claim":"The AKAP18δ scaffold was shown to bidirectionally regulate CaMKIIδ activity at SERCA2 through distinct N- and C-terminal domains, and brain-specific SERCA2 haploinsufficiency was found to produce a hyperdopaminergic phenotype with behavioral abnormalities, extending SERCA2 physiology to neuropsychiatric function.","evidence":"Peptide arrays, SPR, FRET-based CaMKII assays, AAV injection in mice (AKAP18δ); conditional brain Atp2a2+/− mice with in vivo microdialysis and behavioral testing","pmids":["34814703","34104969"],"confidence":"High","gaps":["How SERCA2 haploinsufficiency leads specifically to dopamine elevation mechanistically unclear","Whether AKAP18δ scaffold architecture differs between cardiac and neuronal SERCA2 pools unknown"]},{"year":2022,"claim":"Sigma-1 receptor was identified as a SERCA2 binding partner that promotes its ubiquitin-dependent degradation via Hrd1/Sel1L ERAD at K460/K541, and PDE3A was shown to directly inhibit SERCA2 through actuator domain binding (aa 169–216) independently of its catalytic activity, with disruptor peptides rescuing SERCA2 function in failing hearts.","evidence":"IP-MS; co-IP with mutagenesis of Q615, K460/K541 (Sigmar1-SERCA2); 2-color dSTORM, SPR, peptide arrays, and AAV9 disruptor peptide delivery reducing cardiac mortality (PDE3A-SERCA2)","pmids":["35611810","36876489"],"confidence":"High","gaps":["Whether Sigmar1-mediated SERCA2 degradation is regulated by ligands in vivo unknown","Structural basis of PDE3A actuator domain inhibition not resolved"]},{"year":2023,"claim":"Ser663 was identified as a pathophysiological inhibitory phosphosite elevated in ischemic hearts, MFN2 was shown to enhance SERCA2 activity at MAMs for mitochondrial Ca²⁺ transfer in CD8⁺ T cells, and β-cell SERCA2 loss was found to mislocalize proinsulin processing enzymes, revealing new site-specific regulation, subcellular coupling, and organelle-level consequences of pump dysfunction.","evidence":"Phosphoproteomics of ischemic human hearts with S663 mutagenesis; MFN2-SERCA2 co-IP with conditional Mfn2 ablation in CD8⁺ T cells; β-cell SERCA2 knockout with proinsulin/proPC2 localization and RNA-seq","pmids":["37291092","37738362","37537395"],"confidence":"High","gaps":["Kinase responsible for Ser663 phosphorylation not identified","Structural basis of MFN2-SERCA2 interaction at MAMs unknown","Whether proinsulin trafficking defects occur in human SERCA2-deficient β-cells not tested"]},{"year":null,"claim":"Key unresolved questions include: the identity of the kinase(s) phosphorylating Ser663, the specific O-GlcNAcylation and serotonylation sites on SERCA2, the structural basis of the PDE3A–actuator domain inhibitory interaction, and the mechanism by which partial SERCA2 loss selectively elevates dopamine in the brain.","evidence":"","pmids":[],"confidence":"High","gaps":["Ser663 kinase identity unknown","O-GlcNAcylation and serotonylation sites unmapped by mutagenesis","No high-resolution structure of SERCA2–PDE3A or SERCA2–AKAP18δ complexes","Mechanism linking SERCA2 haploinsufficiency to dopaminergic hyperactivity unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,1,4,5,14,29]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,4,5,10,14]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0,16,26,30]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,1,4,5,10,14,29]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[2,5,6,17,24,32]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,16,22,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,7,8,15,25]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[14,26]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[28]}],"complexes":["SERCA2/PLB complex","SERCA2/AKAP18δ/CaMKIIδ signalosome","SERCA2/PDE3A1/AKAP18 signalosome"],"partners":["PLN","PDE3A","AKAP18","CAMK2D","SIGMAR1","MFN2","CALU","MAPK9"],"other_free_text":[]},"mechanistic_narrative":"ATP2A2 encodes SERCA2, a P-type Ca²⁺-ATPase that actively transports cytosolic Ca²⁺ into the sarcoplasmic/endoplasmic reticulum lumen, functioning as a master regulator of intracellular Ca²⁺ homeostasis across muscle and non-muscle cell types [PMID:2844796, PMID:9891028]. SERCA2 activity is tuned by an extensive network of direct regulators: inhibited by phospholamban (whose stoichiometric ratio to SERCA2 sets contractile kinetics), calumenin binding at luminal loop L4, PDE3A1 docking at the actuator domain, serotonylation by TG2, and phosphorylation at Ser663, while being activated by S-glutathiolation at Cys674, SUMOylation at Lys480/Lys585, JNK2-mediated phosphorylation, and O-GlcNAcylation [PMID:2146166, PMID:9202840, PMID:19740751, PMID:36876489, PMID:15489859, PMID:21900893, PMID:33334123, PMID:37291092]. Haploinsufficiency of ATP2A2 causes Darier disease through disrupted keratinocyte adhesion and differentiation, predisposes to squamous cell carcinogenesis, impairs cardiac contractility, disrupts pancreatic β-cell insulin processing, and produces a hyperdopaminergic neuropsychiatric phenotype [PMID:10080178, PMID:11389134, PMID:10587333, PMID:37537395, PMID:34104969]. SERCA2 is further integrated into supramolecular signaling complexes via AKAP18δ-CaMKIIδ scaffolding at the SR and MFN2-mediated coupling at mitochondria-ER contact sites, and its turnover is controlled by Sigmar1-dependent Hrd1/Sel1L ERAD [PMID:34814703, PMID:37738362, PMID:35611810]."},"prefetch_data":{"uniprot":{"accession":"P16615","full_name":"Sarcoplasmic/endoplasmic reticulum calcium ATPase 2","aliases":["Calcium pump 2","Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform","Endoplasmic reticulum class 1/2 Ca(2+) ATPase"],"length_aa":1042,"mass_kda":114.8,"function":"This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen (PubMed:12542527, PubMed:16402920). Involved in autophagy in response to starvation. Upon interaction with VMP1 and activation, controls ER-isolation membrane contacts for autophagosome formation (PubMed:28890335). Also modulates ER contacts with lipid droplets, mitochondria and endosomes (PubMed:28890335). In coordination with FLVCR2 mediates heme-stimulated switching from mitochondrial ATP synthesis to thermogenesis (By similarity) Involved in the regulation of the contraction/relaxation cycle. Acts as a regulator of TNFSF11-mediated Ca(2+) signaling pathways via its interaction with TMEM64 which is critical for the TNFSF11-induced CREB1 activation and mitochondrial ROS generation necessary for proper osteoclast generation. Association between TMEM64 and SERCA2 in the ER leads to cytosolic Ca(2+) spiking for activation of NFATC1 and production of mitochondrial ROS, thereby triggering Ca(2+) signaling cascades that promote osteoclast differentiation and activation","subcellular_location":"Endoplasmic reticulum membrane; Sarcoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/P16615/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/ATP2A2","classification":"Common Essential","n_dependent_lines":1202,"n_total_lines":1208,"dependency_fraction":0.9950331125827815},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2},{"gene":"CYB5R3","stoichiometry":0.2},{"gene":"DDOST","stoichiometry":0.2},{"gene":"EMC4","stoichiometry":0.2},{"gene":"EMC8","stoichiometry":0.2},{"gene":"MMGT1","stoichiometry":0.2},{"gene":"NSDHL","stoichiometry":0.2},{"gene":"PGRMC1","stoichiometry":0.2},{"gene":"PGRMC2","stoichiometry":0.2},{"gene":"SEC61B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ATP2A2","total_profiled":1310},"omim":[{"mim_id":"621236","title":"RHABDOMYOLYSIS, SUSCEPTIBILITY TO, 2; RHABDO2","url":"https://www.omim.org/entry/621236"},{"mim_id":"620531","title":"SMALL INTEGRAL MEMBRANE PROTEIN 6; SMIM6","url":"https://www.omim.org/entry/620531"},{"mim_id":"620530","title":"ALLREGULIN; ARLN","url":"https://www.omim.org/entry/620530"},{"mim_id":"620429","title":"TRANSMEMBRANE PROTEIN 64; TMEM64","url":"https://www.omim.org/entry/620429"},{"mim_id":"620235","title":"RHABDOMYOLYSIS, SUSCEPTIBILITY TO, 1; RHABDO1","url":"https://www.omim.org/entry/620235"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Nucleoplasm","reliability":"Uncertain"},{"location":"Plasma membrane","reliability":"Uncertain"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Perinuclear theca","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"End piece","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"heart muscle","ntpm":941.9},{"tissue":"skeletal muscle","ntpm":2675.7},{"tissue":"tongue","ntpm":2586.2}],"url":"https://www.proteinatlas.org/search/ATP2A2"},"hgnc":{"alias_symbol":["SERCA2"],"prev_symbol":["ATP2B","DAR"]},"alphafold":{"accession":"P16615","domains":[{"cath_id":"2.70.150.10","chopping":"3-42_117-240","consensus_level":"medium","plddt":89.9402,"start":3,"end":240},{"cath_id":"3.40.50.1000","chopping":"331-356_602-737","consensus_level":"high","plddt":89.1815,"start":331,"end":737},{"cath_id":"3.40.1110.10","chopping":"361-598","consensus_level":"medium","plddt":91.339,"start":361,"end":598},{"cath_id":"1.20.1110.10","chopping":"758-809_828-992_1011-1042","consensus_level":"medium","plddt":85.5494,"start":758,"end":1042},{"cath_id":"1.10.287","chopping":"48-112","consensus_level":"medium","plddt":78.2685,"start":48,"end":112},{"cath_id":"1.10.287","chopping":"256-307","consensus_level":"medium","plddt":73.6575,"start":256,"end":307}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16615","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16615-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16615-F1-predicted_aligned_error_v6.png","plddt_mean":85.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ATP2A2","jax_strain_url":"https://www.jax.org/strain/search?query=ATP2A2"},"sequence":{"accession":"P16615","fasta_url":"https://rest.uniprot.org/uniprotkb/P16615.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16615/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16615"}},"corpus_meta":[{"pmid":"10080178","id":"PMC_10080178","title":"Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10080178","citation_count":576,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9891028","id":"PMC_9891028","title":"Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9891028","citation_count":213,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16105684","id":"PMC_16105684","title":"Modulating sarco(endo)plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: cell biological implications.","date":"2005","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/16105684","citation_count":181,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10441323","id":"PMC_10441323","title":"Spectrum of novel ATP2A2 mutations in patients with Darier's disease.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10441323","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10441325","id":"PMC_10441325","title":"ATP2A2 mutations in Darier's disease and their relationship to neuropsychiatric phenotypes.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10441325","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10441324","id":"PMC_10441324","title":"ATP2A2 mutations in Darier's disease: variant cutaneous phenotypes are associated with missense mutations, but neuropsychiatric features are independent of mutation class.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10441324","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11121153","id":"PMC_11121153","title":"Mosaicism for ATP2A2 mutations causes segmental Darier's disease.","date":"2000","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/11121153","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10970890","id":"PMC_10970890","title":"Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10970890","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35836807","id":"PMC_35836807","title":"SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35836807","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11389134","id":"PMC_11389134","title":"Squamous cell tumors in mice heterozygous for a null allele of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11389134","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25593322","id":"PMC_25593322","title":"Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25593322","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9202840","id":"PMC_9202840","title":"The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility.","date":"1997","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/9202840","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11168576","id":"PMC_11168576","title":"Darier disease--novel mutations in ATP2A2 and genotype-phenotype correlation.","date":"2001","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/11168576","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18388909","id":"PMC_18388909","title":"Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats.","date":"2008","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18388909","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37738362","id":"PMC_37738362","title":"Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8+ T cell metabolic fitness and function in tumors.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37738362","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27489309","id":"PMC_27489309","title":"SERCA2 Deficiency Impairs Pancreatic β-Cell Function in Response to Diet-Induced Obesity.","date":"2016","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/27489309","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8523431","id":"PMC_8523431","title":"Reciprocal changes in the postnatal expression of the sarcolemmal Na+-Ca(2+)-exchanger and SERCA2 in rat heart.","date":"1995","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/8523431","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11387203","id":"PMC_11387203","title":"Plasticity and adaptation of Ca2+ signaling and Ca2+-dependent exocytosis in SERCA2(+/-) mice.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11387203","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16204033","id":"PMC_16204033","title":"Haploinsufficiency of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump, predisposes mice to squamous cell tumors via a novel mode of cancer susceptibility.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16204033","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17005265","id":"PMC_17005265","title":"New perspectives on the role of SERCA2's Ca2+ affinity in cardiac function.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17005265","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17116488","id":"PMC_17116488","title":"Alterations in the ATP2A2 gene in correlation with colon and lung cancer.","date":"2006","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17116488","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28035777","id":"PMC_28035777","title":"Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease.","date":"2017","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/28035777","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23320567","id":"PMC_23320567","title":"Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania.","date":"2013","source":"BMC public health","url":"https://pubmed.ncbi.nlm.nih.gov/23320567","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19740751","id":"PMC_19740751","title":"Characterization of calumenin-SERCA2 interaction in mouse cardiac sarcoplasmic reticulum.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19740751","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23913153","id":"PMC_23913153","title":"Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy.","date":"2013","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/23913153","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31145786","id":"PMC_31145786","title":"Newborn screening for sickle cell disease: an innovative pilot program to improve child survival in Dar es Salaam, Tanzania.","date":"2019","source":"International health","url":"https://pubmed.ncbi.nlm.nih.gov/31145786","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21113058","id":"PMC_21113058","title":"Mitochondrial transcription factors TFAM and TFB2M regulate Serca2 gene transcription.","date":"2010","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21113058","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35414872","id":"PMC_35414872","title":"A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides.","date":"2022","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/35414872","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33334123","id":"PMC_33334123","title":"JNK2, a Newly-Identified SERCA2 Enhancer, Augments an Arrhythmic [Ca2+]SR Leak-Load Relationship.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/33334123","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34814703","id":"PMC_34814703","title":"AKAP18δ Anchors and Regulates CaMKII Activity at Phospholamban-SERCA2 and RYR.","date":"2021","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/34814703","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27997597","id":"PMC_27997597","title":"Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27997597","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2146166","id":"PMC_2146166","title":"Co-expression of slow-twitch/cardiac muscle Ca2(+)-ATPase (SERCA2) and phospholamban.","date":"1990","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/2146166","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11244492","id":"PMC_11244492","title":"Exclusion of the Darier's disease gene, ATP2A2, as a common susceptibility gene for bipolar disorder.","date":"2001","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/11244492","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15362510","id":"PMC_15362510","title":"Increased inhibition of SERCA2 by phospholamban in the type I diabetic heart.","date":"2004","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15362510","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25181347","id":"PMC_25181347","title":"Epigenetic switch at atp2a2 and myh7 gene promoters in pressure overload-induced heart failure.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25181347","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22277942","id":"PMC_22277942","title":"SERCA2-controlled Ca²+-dependent keratinocyte adhesion and differentiation is mediated via the sphingolipid pathway: a therapeutic target for Darier's disease.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22277942","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22045735","id":"PMC_22045735","title":"Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes.","date":"2011","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22045735","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37291092","id":"PMC_37291092","title":"SERCA2 phosphorylation at serine 663 is a key regulator of Ca2+ homeostasis in heart diseases.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37291092","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35611810","id":"PMC_35611810","title":"Sigma-1 receptor attenuates osteoclastogenesis by promoting ER-associated degradation of SERCA2.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35611810","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15099360","id":"PMC_15099360","title":"Mutational analysis of the ATP2A2 gene in two Darier disease families with intrafamilial variability.","date":"2004","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15099360","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32375037","id":"PMC_32375037","title":"Islet O-GlcNAcylation Is Required for Lipid Potentiation of Insulin Secretion through SERCA2.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32375037","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18562801","id":"PMC_18562801","title":"Calumenin interacts with SERCA2 in rat cardiac sarcoplasmic reticulum.","date":"2008","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/18562801","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9461473","id":"PMC_9461473","title":"A novel E box/AT-rich element is required for muscle-specific expression of the sarcoplasmic reticulum Ca2+-ATPase (SERCA2) gene.","date":"1998","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9461473","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12829175","id":"PMC_12829175","title":"The MKK6-p38 MAPK pathway prolongs the cardiac contractile calcium transient, downregulates SERCA2, and activates NF-AT.","date":"2003","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/12829175","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17287366","id":"PMC_17287366","title":"Phenylephrine hypertrophy, Ca2+-ATPase (SERCA2), and Ca2+ signaling in neonatal rat cardiac myocytes.","date":"2007","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17287366","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16236312","id":"PMC_16236312","title":"PKC-independent signal transduction pathways increase SERCA2 expression in adult rat cardiomyocytes.","date":"2005","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/16236312","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12131569","id":"PMC_12131569","title":"Correlates of plasma HIV-1 RNA viral load among HIV-1-seropositive women in Dar es Salaam, Tanzania.","date":"2002","source":"Journal of acquired immune deficiency syndromes (1999)","url":"https://pubmed.ncbi.nlm.nih.gov/12131569","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28234969","id":"PMC_28234969","title":"The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28234969","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11390201","id":"PMC_11390201","title":"Novel mutations of ATP2A2 gene in Japanese patients of Darier's disease.","date":"2001","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/11390201","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26154588","id":"PMC_26154588","title":"Somatic ATP2A2 mutation in a case of papular acantholytic dyskeratosis: mosaic Darier disease.","date":"2015","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26154588","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32116663","id":"PMC_32116663","title":"Role of TG2-Mediated SERCA2 Serotonylation on Hypoxic Pulmonary Vein Remodeling.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32116663","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34104969","id":"PMC_34104969","title":"Brain-specific heterozygous loss-of-function of ATP2A2, endoplasmic reticulum Ca2+ pump responsible for Darier's disease, causes behavioral abnormalities and a hyper-dopaminergic state.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34104969","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31778646","id":"PMC_31778646","title":"DEL-1 ameliorates high-fat diet-induced insulin resistance in mouse skeletal muscle through SIRT1/SERCA2-mediated ER stress suppression.","date":"2019","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31778646","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16552539","id":"PMC_16552539","title":"Five mutations of ATP2A2 gene in Chinese patients with Darier's disease and a literature review of 86 cases reported in China.","date":"2006","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/16552539","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20737827","id":"PMC_20737827","title":"Understanding women's experiences of distress during pregnancy in Dar es Salaam, Tanzania.","date":"2010","source":"Tanzania journal of health research","url":"https://pubmed.ncbi.nlm.nih.gov/20737827","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32446846","id":"PMC_32446846","title":"LncRNA MEG3-210 regulates endometrial stromal cells migration, invasion and apoptosis through p38 MAPK and PKA/SERCA2 signalling via interaction with Galectin-1 in endometriosis.","date":"2020","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32446846","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25008120","id":"PMC_25008120","title":"Extracellular signal-regulated kinase activation during cardiac hypertrophy reduces sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) transcription.","date":"2014","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25008120","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17516033","id":"PMC_17516033","title":"Time course of changes in the expression of DHPR, RyR(2), and SERCA2 after myocardial infarction in the rat left ventricle.","date":"2007","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17516033","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31758704","id":"PMC_31758704","title":"Inactivation of Cys674 in SERCA2 increases BP by inducing endoplasmic reticulum stress and soluble epoxide hydrolase.","date":"2020","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31758704","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20571519","id":"PMC_20571519","title":"Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.","date":"2010","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20571519","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27000018","id":"PMC_27000018","title":"Renal abnormalities among HIV infected children at Muhimbili National Hospital (MNH)-Dar es Salaam, Tanzania.","date":"2016","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/27000018","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29111880","id":"PMC_29111880","title":"Early marriage and cultural constructions of adulthood in two slums in Dar es Salaam.","date":"2017","source":"Culture, health & sexuality","url":"https://pubmed.ncbi.nlm.nih.gov/29111880","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32035136","id":"PMC_32035136","title":"Inactivation of cysteine 674 in the SERCA2 accelerates experimental aortic aneurysm.","date":"2020","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/32035136","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35325010","id":"PMC_35325010","title":"Toxoplasma gondii phosphatidylserine flippase complex ATP2B-CDC50.4 critically participates in microneme exocytosis.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/35325010","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30575439","id":"PMC_30575439","title":"HIF-1 regulation of miR-29c impairs SERCA2 expression and cardiac contractility.","date":"2018","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30575439","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35024244","id":"PMC_35024244","title":"LncEDCH1 improves mitochondrial function to reduce muscle atrophy by interacting with SERCA2.","date":"2021","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/35024244","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36983052","id":"PMC_36983052","title":"Cadmium Disrupted ER Ca2+ Homeostasis by Inhibiting SERCA2 Expression and Activity to Induce Apoptosis in Renal Proximal Tubular Cells.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36983052","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21057045","id":"PMC_21057045","title":"Silencing calcineurin A subunit reduces SERCA2 expression in cardiac myocytes.","date":"2010","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21057045","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8930809","id":"PMC_8930809","title":"Molecular cloning and analysis of the human cardiac sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA2) gene promoter.","date":"1996","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/8930809","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15713129","id":"PMC_15713129","title":"High frequency of partial DIIIa and DAR alleles found in sickle cell disease patients suggests increased risk of alloimmunization to RhD.","date":"2005","source":"Transfusion medicine (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15713129","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36224448","id":"PMC_36224448","title":"DAR-PCR: a new tool for efficient retrieval of unknown flanking genomic DNA.","date":"2022","source":"AMB Express","url":"https://pubmed.ncbi.nlm.nih.gov/36224448","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15169625","id":"PMC_15169625","title":"Dispersion of ventricular mRNA of RyR2 and SERCA2 associated with arrhythmogenesis in rats.","date":"2004","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/15169625","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36876489","id":"PMC_36876489","title":"Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/36876489","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12072062","id":"PMC_12072062","title":"Mutation analysis of the ATP2A2 gene in Taiwanese patients with Darier's disease.","date":"2002","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12072062","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22293579","id":"PMC_22293579","title":"Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.","date":"2011","source":"Antiviral therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22293579","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23516438","id":"PMC_23516438","title":"Low density lipoproteins promote unstable calcium handling accompanied by reduced SERCA2 and connexin-40 expression in cardiomyocytes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23516438","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27106560","id":"PMC_27106560","title":"Loss of function mutations in ATP2A2 and psychoses: A case report and literature survey.","date":"2016","source":"Psychiatry and clinical neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/27106560","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31120957","id":"PMC_31120957","title":"CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31120957","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37195706","id":"PMC_37195706","title":"Association of Somatic ATP2A2 Damaging Variants With Grover Disease.","date":"2023","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/37195706","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36561988","id":"PMC_36561988","title":"Highly expressed SERCA2 triggers tumor cell autophagy and is a druggable vulnerability in triple-negative breast cancer.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/36561988","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33591571","id":"PMC_33591571","title":"Inactivation of SERCA2 Cys674 accelerates aortic aneurysms by suppressing PPARγ.","date":"2021","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33591571","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31826997","id":"PMC_31826997","title":"Different Degrees of 5'-to-3' DAR Interactions Modulate Zika Virus Genome Cyclization and Host-Specific Replication.","date":"2020","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/31826997","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25957324","id":"PMC_25957324","title":"Prevalence and risk factors of cervical squamous intraepithelial lesions among HIV-infected women in Dar es Salaam, Tanzania.","date":"2015","source":"International journal of STD & AIDS","url":"https://pubmed.ncbi.nlm.nih.gov/25957324","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9139974","id":"PMC_9139974","title":"Modulation of SERCA2 expression by thyroid hormone and norepinephrine in cardiocytes: role of contractility.","date":"1997","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9139974","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22096575","id":"PMC_22096575","title":"SERCA2 regulates non-CF and CF airway epithelial cell response to ozone.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22096575","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22413864","id":"PMC_22413864","title":"Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERCA2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease.","date":"2012","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22413864","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38273339","id":"PMC_38273339","title":"Incidence of catheter-associated urinary tract infections by Gram-negative bacilli and their ESBL and carbapenemase production in specialized hospitals of Bahir Dar, northwest Ethiopia.","date":"2024","source":"Antimicrobial resistance and infection control","url":"https://pubmed.ncbi.nlm.nih.gov/38273339","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37537395","id":"PMC_37537395","title":"SERCA2 regulates proinsulin processing and processing enzyme maturation in pancreatic beta cells.","date":"2023","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/37537395","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15186327","id":"PMC_15186327","title":"Identification of mutations in the ATP2A2 gene in patients with Darier's disease from Hungary.","date":"2004","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15186327","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25968337","id":"PMC_25968337","title":"Hypoxia-driven sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) downregulation depends on low-density lipoprotein receptor-related protein 1 (LRP1)-signalling in cardiomyocytes.","date":"2015","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25968337","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25915065","id":"PMC_25915065","title":"Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25915065","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31273377","id":"PMC_31273377","title":"Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring.","date":"2019","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/31273377","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36521248","id":"PMC_36521248","title":"Lathyrol promotes ER stress-induced apoptosis and proliferation inhibition in lung cancer cells by targeting SERCA2.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36521248","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32489586","id":"PMC_32489586","title":"Metoprolol alleviates arginine vasopressin-induced cardiomyocyte hypertrophy by upregulating the AKT1-SERCA2 cascade in H9C2 cells.","date":"2020","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/32489586","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38909775","id":"PMC_38909775","title":"Novel SERCA2 inhibitor Diphyllin displays anti-tumor effect in non-small cell lung cancer by promoting endoplasmic reticulum stress and mitochondrial dysfunction.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38909775","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21964539","id":"PMC_21964539","title":"Regulation and rate limiting mechanisms of Ca2+ ATPase (SERCA2) expression in cardiac myocytes.","date":"2011","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21964539","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35646520","id":"PMC_35646520","title":"The substitution of SERCA2 redox cysteine 674 promotes pulmonary vascular remodeling by activating IRE1α/XBP1s pathway.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35646520","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35222514","id":"PMC_35222514","title":"Healthcare Workers' Knowledge and Resource Availability for Care of Sickle Cell Disease in Dar es Salaam, Tanzania.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35222514","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29870688","id":"PMC_29870688","title":"Loss of ATP2A2 Allows Herpes Simplex Virus 1 Infection of a Human Epidermis Model by Disrupting Innate Immunity and Barrier Function.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29870688","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36157491","id":"PMC_36157491","title":"Intranuclear cardiac troponin I plays a functional role in regulating Atp2a2 expression in cardiomyocytes.","date":"2021","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/36157491","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25056061","id":"PMC_25056061","title":"Biological insights from 108 schizophrenia-associated genetic loci.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25056061","citation_count":5878,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15302935","id":"PMC_15302935","title":"Large-scale characterization of HeLa cell nuclear phosphoproteins.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15302935","citation_count":1159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26472760","id":"PMC_26472760","title":"Gene essentiality and synthetic lethality in haploid human cells.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26472760","citation_count":657,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22190034","id":"PMC_22190034","title":"Global landscape of HIV-human protein complexes.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22190034","citation_count":593,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489859","id":"PMC_15489859","title":"S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide.","date":"2004","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15489859","citation_count":541,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17110338","id":"PMC_17110338","title":"Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17110338","citation_count":517,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15071553","id":"PMC_15071553","title":"Biology, structure and mechanism of P-type ATPases.","date":"2004","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15071553","citation_count":447,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26638075","id":"PMC_26638075","title":"A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26638075","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22679139","id":"PMC_22679139","title":"Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome.","date":"2012","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/22679139","citation_count":429,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26871637","id":"PMC_26871637","title":"Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26871637","citation_count":423,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18464913","id":"PMC_18464913","title":"A genome-wide association study identifies protein quantitative trait loci (pQTLs).","date":"2008","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18464913","citation_count":390,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10587333","id":"PMC_10587333","title":"Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a.","date":"1999","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/10587333","citation_count":386,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29656893","id":"PMC_29656893","title":"DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29656893","citation_count":379,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2844796","id":"PMC_2844796","title":"Molecular cloning of cDNAs from human kidney coding for two alternatively spliced products of the cardiac Ca2+-ATPase gene.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2844796","citation_count":332,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25036637","id":"PMC_25036637","title":"A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25036637","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21900893","id":"PMC_21900893","title":"SUMO1-dependent modulation of SERCA2a in heart failure.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21900893","citation_count":320,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54901,"output_tokens":8965,"usd":0.149589},"stage2":{"model":"claude-opus-4-6","input_tokens":12851,"output_tokens":5625,"usd":0.30732},"total_usd":0.917956,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66575,"output_tokens":9772,"usd":0.173152},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13876,"output_tokens":4902,"usd":0.287895}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Mutations in ATP2A2, encoding the sarco/endoplasmic reticulum Ca2+-ATPase type 2 (SERCA2), cause Darier disease; frameshift, splice-site, and missense mutations in functional domains disrupt Ca2+-signalling required for keratinocyte cell-to-cell adhesion and differentiation.\",\n      \"method\": \"Mutation screening (sequencing, gel electrophoresis) of ATP2A2 in Darier disease families; identification of 13 mutations in functional domains\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original disease gene identification with multiple mutation classes in functional domains, replicated across multiple cohorts\",\n      \"pmids\": [\"10080178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"SERCA2 (slow-twitch/cardiac Ca2+-ATPase) requires interaction with phospholamban for inhibition: co-expression of phospholamban with SERCA2 in COS-1 cells lowered the Ca2+-affinity of SERCA2, demonstrating a direct inhibitory protein-protein interaction.\",\n      \"method\": \"Transient co-transfection of SERCA2 and phospholamban cDNAs in COS-1 cells; Ca2+-transport measurement in isolated microsomes\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in heterologous expression system with functional assay; foundational mechanistic study replicated extensively\",\n      \"pmids\": [\"2146166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The relative ratio of phospholamban to SERCA2 is a critical determinant of myocardial contractility: atrial muscle with a 4.2-fold lower phospholamban:SERCA2 ratio shows faster contraction/relaxation, and phospholamban knockout hearts (zero ratio) show enhanced contractility versus wild-type.\",\n      \"method\": \"Comparison of contractile parameters in murine atrial vs. ventricular muscle and phospholamban knockout vs. wild-type isolated hearts\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model (PLB KO) with defined functional phenotype, replicated in two independent comparisons\",\n      \"pmids\": [\"9202840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Heterozygous null mutation of SERCA2 gene reduces SERCA2 mRNA by ~45% and protein by ~35% in mouse heart, and impairs cardiac contractility and relaxation (reduced arterial pressure, systolic ventricular pressure, and dP/dt), demonstrating that two functional copies of ATP2A2 are required for normal Ca2+ sequestering activity.\",\n      \"method\": \"Gene targeting (heterozygous knockout mice); RNase protection, Western blotting, biochemical Ca2+ uptake assay, in vivo cardiac pressure transducers\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — clean KO model with multiple orthogonal methods measuring protein, RNA, and functional Ca2+ transport plus hemodynamics\",\n      \"pmids\": [\"9891028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Loss of one copy of SERCA2 reduces SR Ca2+ stores and Ca2+ release in cardiomyocytes by 40-60%, slows myocyte shortening and relengthening by ~40%, and triggers compensatory reductions in phospholamban with increased basal phosphorylation (Ser-16 ~2-fold, Thr-17 ~2.1-fold) and upregulation of the Na+-Ca2+ exchanger.\",\n      \"method\": \"SERCA2(+/-) mouse model; Ca2+ imaging in isolated cardiomyocytes, immunoblotting for PLB phosphorylation, Na+/Ca2+ exchanger current density measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with multiple orthogonal functional and biochemical readouts in isolated cardiomyocytes\",\n      \"pmids\": [\"10970890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"SERCA2 haploinsufficiency (Atp2a2+/- mice) causes squamous cell tumors of the forestomach, esophagus, oral mucosa, tongue and skin in 13/14 heterozygous mice but not wild-type controls, establishing that SERCA2 Ca2+ homeostasis perturbation can serve as a primary initiating event in cancer without loss of heterozygosity.\",\n      \"method\": \"Atp2a2+/- heterozygous mouse model; Western blotting, immunohistochemistry, pathological tumor characterization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined genetic model with clear tumor phenotype, LOH excluded by LOH analysis\",\n      \"pmids\": [\"11389134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In SERCA2(+/-) mouse cells, the shortened Ca2+ transient due to SERCA2 deficiency is compensated by upregulation of specific plasma membrane Ca2+ pump isoforms; additionally, agonist-stimulated exocytosis is maintained by adaptation in Ca2+ sensors (synaptotagmins I and III), making exocytosis ~10-fold more sensitive to Ca2+.\",\n      \"method\": \"SERCA2(+/-) mouse model; Ca2+ imaging, exocytosis assays, Western blotting for synaptotagmins and plasma membrane Ca2+ pumps\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with multiple orthogonal methods revealing compensatory mechanisms\",\n      \"pmids\": [\"11387203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Calumenin (an EF-hand Ca2+-binding protein in the SR lumen) directly interacts with SERCA2 and inhibits its Ca2+ uptake activity; the interaction is favored in the E1 state of SERCA2 and requires residues 132-222 of calumenin and the L4 luminal loop (853-892 aa) of SERCA2.\",\n      \"method\": \"Co-immunoprecipitation, GST-pulldown with deletion fragments, oxalate-supported Ca2+ uptake assay in calumenin-knockdown HL-1 cells, Ca2+ imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus GST-pulldown mapping, functional rescue with defined molecular interaction site\",\n      \"pmids\": [\"19740751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Phosphodiesterase 3A1 (PDE3A1) forms part of a SERCA2/AKAP18 signalosome in human cardiac SR and its interaction with SERCA2 is regulated by PKA phosphorylation at Ser-292/Ser-293 in the unique N-terminal extension of PDE3A1; this interaction controls local cAMP, PLB phosphorylation, and SERCA2 activity.\",\n      \"method\": \"Gel filtration chromatography, co-immunoprecipitation, recombinant protein interaction assay, site-directed mutagenesis (Ser-to-Ala substitutions), N-terminal deletion of PDE3A1, immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutagenesis identifying specific phosphorylation site and N-terminal domain required for interaction\",\n      \"pmids\": [\"25593322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AKAP18δ anchors and directly regulates CaMKIIδ activity at the SERCA2-PLN complex via two distinct regions: an N-terminal region (AKAP18δ-N) inhibits CaMKIIδ and slows Ca2+ reuptake, while a C-terminal region (AKAP18δ-C) activates CaMKIIδ and facilitates faster Ca2+ reuptake by SERCA2.\",\n      \"method\": \"Peptide arrays, surface plasmon resonance, immunoprecipitation, FRET-based CaMKII activity assay, SR vesicle fluorescence imaging, proximity ligation assay, AAV injection in mice\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including structural mapping, functional assays and in vivo validation\",\n      \"pmids\": [\"34814703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"JNK2 (but not JNK1) directly associates with and phosphorylates SERCA2, enhancing SERCA2-ATPase activity via increased maximal rate without altering Ca2+ affinity, thereby elevating SR Ca2+ content in a CaMKII-independent manner.\",\n      \"method\": \"Confocal Ca2+ imaging, biochemistry (co-immunoprecipitation, phosphorylation assays), JNK isoform-specific manipulation, CaMKII inhibition, dual Ca2+/voltage optical mapping in intact hearts\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with isoform-specific dissection and mechanistic controls\",\n      \"pmids\": [\"33334123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PDE3A directly binds to the actuator domain of SERCA2 (amino acids 169-216) via PDE3A amino acids 277-402, and this binding inhibits SERCA2 activity independently of PDE3A catalytic activity; disrupting this interaction with a peptide (OptF) increases SERCA2 activity and reduces cardiac mortality after aortic banding in mice.\",\n      \"method\": \"Proximity ligation assay, co-IP, peptide arrays, surface plasmon resonance, confocal/STORM microscopy, HEK293 vesicle functional assay, rAAV9 in vivo treatment in two randomized controlled preclinical trials (n=148 mice)\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding mapped to specific domains, functional reconstitution in vesicles, replicated in two independent in vivo trials\",\n      \"pmids\": [\"36876489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SERCA2 phosphorylation at serine 663 increases in ischemic human and mouse hearts; preventing S663 phosphorylation significantly increases SERCA2 activity, counteracts cytosolic and mitochondrial Ca2+ overload, and protects against cell death in human cell lines.\",\n      \"method\": \"Phosphorylation site identification in human ischemic heart tissue; mutagenesis preventing S663 phosphorylation; SERCA2 activity assays; Ca2+ measurements in multiple human cell lines; infarct size measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — phosphosite identified in human tissue, mutagenesis confirms functional role, replicated across cell lines with multiple readouts\",\n      \"pmids\": [\"37291092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mitochondrial transcription factors TFAM and TFB2M bind to the Serca2 gene promoter (at -122 to -114 nt and -122 to -117 nt, respectively) in rat cardiomyocyte nuclei and regulate SERCA2 transcription; mutation of these binding sites decreased Serca2 transcription.\",\n      \"method\": \"Chromatin immunoprecipitation, fluorescence correlation spectroscopy, promoter mutation/reporter assays, immunostaining, overexpression in neonatal rat cardiomyocytes\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and mutagenesis in cardiomyocytes; single lab\",\n      \"pmids\": [\"21113058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"An E box/AT-rich element at -1115 bp of the SERCA2 gene promoter is critical for muscle-specific enhancer activity; the element binds a muscle-induced nuclear protein and cooperates with CArG and MCAT elements to drive maximal SERCA2 transcription in muscle cells.\",\n      \"method\": \"Deletion analysis, gel mobility shift assays, site-directed mutagenesis, reporter gene (CAT) transfection in Sol8 myotubes\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis plus gel shift assays in muscle cells; single lab\",\n      \"pmids\": [\"9461473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Calcineurin A (CNA) α- or β-subunit, acting through the NFAT pathway, regulates transcription of SERCA2 in cardiac myocytes: silencing CNA with siRNA reduces SERCA2 expression, and NFAT displacement from calcineurin (with INCA-6) also reduces SERCA2; conversely, calcineurin activation by cytosolic Ca2+ rise increases SERCA2 expression.\",\n      \"method\": \"siRNA gene silencing of CNA isoforms, NFAT inhibitor (INCA-6), cyclosporine inhibition, luciferase reporter assay, Western blotting in neonatal rat cardiac myocytes; in-silico identification of NFAT binding sites in SERCA2 promoter\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gene silencing with specific siRNA and pharmacological corroboration; single lab\",\n      \"pmids\": [\"21057045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ERK1/2 activation during cardiac hypertrophy represses SERCA2 transcription via NF-κB; pharmacological ERK inhibition preserves SERCA2 mRNA during hypertrophy, and NF-κB activation alone is sufficient to reduce SERCA2 mRNA in cardiomyocytes.\",\n      \"method\": \"Pharmacological ERK inhibition, NF-κB activation, RT-PCR, reporter assays in neonatal rat ventricular myocytes\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic pathway dissection; single lab\",\n      \"pmids\": [\"25008120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Epigenetic modifications (H3K4me2, H3K9me2, H3K27me3, H3K36me2 histone methylation; DNMT1, DNMT3b, MeCP2 recruitment) at the Atp2a2 promoter are associated with reduced SERCA2a expression in pressure overload-induced heart failure, with reduced KDM2A at the Atp2a2 promoter after 8 weeks of TAC.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for histone marks and DNA methylation machinery at Atp2a2 promoter in TAC mouse model; qPCR, Western blotting\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP in disease model with multiple histone marks; single lab\",\n      \"pmids\": [\"25181347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SERCA2 is O-GlcNAcylated in pancreatic β cells (confirmed in mice and humans), and this modification is required for lipid potentiation of insulin secretion; SERCA2 pharmacological activation rescues palmitate-stimulated insulin secretion in OGT-deficient β cells.\",\n      \"method\": \"O-GlcNAc proteomics in mouse and human islets, genetic OGT deletion in β cells, SERCA2 activator rescue experiment, in vitro and in vivo insulin secretion assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — post-translational modification identified by mass spectrometry with functional validation in genetic model; single lab\",\n      \"pmids\": [\"32375037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Transglutaminase 2 (TG2) serotonylates SERCA2 under hypoxia, inhibiting SERCA2 activity and increasing Ca2+ influx through TRPC6, promoting pulmonary vascular remodeling; TG2-mediated SERCA2 serotonylation was confirmed by co-IP in vivo and in vitro.\",\n      \"method\": \"Co-immunoprecipitation, TG2 gene silencing/overexpression, TG2 knockout mice, Ca2+ measurement with Fluo-4AM, SERCA2 activity assay, Western blot, RT-PCR\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with genetic manipulation in vivo and in vitro; single lab\",\n      \"pmids\": [\"32116663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Sigma-1 receptor (Sigmar1) interacts with SERCA2 (at Q615 of SERCA2) and promotes its ubiquitin-dependent proteasomal degradation via Hrd1/Sel1L-dependent ERAD; ubiquitination at SERCA2 K460 and K541 mediates degradation, and this reduces osteoclastogenesis.\",\n      \"method\": \"IP-mass spectrometry, co-immunoprecipitation, site-directed mutagenesis (Q615A, K460R/K541R), Sigmar1 KO and OE mice, ubiquitination assay, ERAD pathway inhibition\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — IP-MS plus mutagenesis identifying specific binding and ubiquitination residues, with genetic models\",\n      \"pmids\": [\"35611810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Inactivation of Cys674 in SERCA2 (C674S knock-in mice) increases blood pressure by inducing ER stress and upregulating soluble epoxide hydrolase (sEH) in renal cortex, leading to decreased dopamine D1 receptor expression and impaired sodium excretion.\",\n      \"method\": \"Heterozygous SERCA2 C674S knock-in (SKI) mouse; BP measurement, urine analysis, ER stress markers, Na+/K+-ATPase activity, pharmacological ER stress inhibition\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — site-specific knock-in model with defined mechanistic pathway from C674 oxidation to ER stress to hypertension\",\n      \"pmids\": [\"31758704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Inactivation of SERCA2 Cys674 (C674S knock-in) causes intracellular Ca2+ accumulation that activates calcineurin, promoting nuclear translocation of NFAT and NF-κB, inducing SMC phenotypic modulation, and accelerating angiotensin II-induced aortic aneurysm.\",\n      \"method\": \"SERCA2 C674S knock-in mice, calcineurin inhibition, NFAT/NF-κB nuclear translocation assays, SMC phenotypic modulation markers, aortic aneurysm model\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — site-specific knock-in with mechanistic pathway dissection using pharmacological inhibitors\",\n      \"pmids\": [\"32035136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MFN2 enhances mitochondria-ER contact by interacting with ER-embedded SERCA2, facilitating mitochondrial Ca2+ influx for efficient mitochondrial metabolism in CD8+ T cells; MFN2 also stimulates SERCA2's ER Ca2+ retrieval activity to prevent excessive mitochondrial Ca2+ accumulation.\",\n      \"method\": \"Co-immunoprecipitation (MFN2-SERCA2), genetic ablation of Mfn2 in CD8+ T cells, SERCA2 knockout mice, Ca2+ imaging, mitochondrial function assays\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus genetic KO models with orthogonal functional assays\",\n      \"pmids\": [\"37738362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HIF-1 upregulates miR-29c in cardiomyocytes, which in turn reduces SERCA2 expression and Ca2+ reuptake; antagonism of miR-29c with an antimir improved cardiac contractility and SERCA2 expression in HIF transgenic mice.\",\n      \"method\": \"HIF-1 transgenic mouse with inducible cardiomyocyte-specific HIF-1 expression; miRNA screening, antimir administration, Ca2+ reuptake assay, echocardiography\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with antimir rescue; miR-29c to SERCA2 axis established but single lab\",\n      \"pmids\": [\"30575439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SERCA2 mutant proteins identical to those found in Darier disease patients are less soluble, aggregate, and are more polyubiquitinated; when transduced into primary human keratinocytes, these mutant SERCA2 aggregates elicit ER stress, cause cell rounding/detachment, and induce apoptosis.\",\n      \"method\": \"Systematic mutagenesis (DD patient mutations), solubility/aggregation assays, polyubiquitination assay, ER stress markers, adenoviral transduction into primary human keratinocytes, apoptosis assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutagenesis in primary human cells with multiple readouts; single lab\",\n      \"pmids\": [\"22045735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SERCA2 inhibition (via thapsigargin or siRNA to SERCA2b) increases sphingosine levels and decreases SPHK1 expression in keratinocytes; inhibiting sphingosine lyase rescues defects in keratinocyte differentiation, E-cadherin localization, desmoplakin translocation, and ER Ca2+ sequestration caused by SERCA2 inhibition.\",\n      \"method\": \"Thapsigargin treatment, siRNA knockdown of SERCA2b, sphingolipid pathway inhibition, immunofluorescence for E-cadherin/desmoplakin, Ca2+ imaging, Western blot\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and siRNA approaches in keratinocytes with multiple readouts; single lab\",\n      \"pmids\": [\"22277942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SERCA2 deficiency in pancreatic β cells impairs insulin secretion, glucose-induced Ca2+ mobilization, ER Ca2+ stores, and β-cell mass/proliferation under high-fat diet; SERCA2 activation with a small-molecule allosteric activator increases ER Ca2+ storage and rescues tunicamycin-induced β-cell death.\",\n      \"method\": \"SERCA2 heterozygous mice (S2HET) on high-fat diet; glucose tolerance tests, Ca2+ imaging in islets, insulin secretion assays, β-cell mass quantification, small-molecule SERCA2 activator\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with multiple orthogonal functional readouts plus pharmacological rescue\",\n      \"pmids\": [\"27489309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Beta cell-specific deletion of SERCA2 impairs proinsulin processing by reducing active forms of prohormone convertases PC1/3 and PC2, and causes mislocation and abnormal accumulation of proinsulin and proPC2 in the ERGIC and cis-Golgi, linking ER Ca2+ homeostasis to proinsulin trafficking and maturation.\",\n      \"method\": \"Beta cell-specific SERCA2 knockout mice (βS2KO), ER Ca2+ imaging, RNA-seq, immunofluorescence for proinsulin/proPC2/Golgi markers, INS-1 SERCA2-deficient cell line, human cadaveric islets\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type specific KO with multiple orthogonal methods including human islet validation\",\n      \"pmids\": [\"37537395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Brain-specific heterozygous Atp2a2 knockout mice show slower decay of cytosolic Ca2+ after depolarization in neurons, and elevated extracellular dopamine in the nucleus accumbens (measured by in vivo microdialysis), establishing that SERCA2 haploinsufficiency in the brain prolongs Ca2+ transients and enhances dopamine signaling.\",\n      \"method\": \"Brain-specific conditional knockout mice; ER membrane Ca2+ uptake assay, cytosolic Ca2+ decay imaging in neurons, in vivo microdialysis, behavioral testing\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO with direct Ca2+ measurements and in vivo neurotransmitter measurements\",\n      \"pmids\": [\"34104969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LncEDCH1 binds directly to SERCA2 protein in skeletal muscle, enhances SERCA2 protein stability and increases SERCA2 activity, improving mitochondrial efficiency possibly through SERCA2-mediated AMPK pathway activation.\",\n      \"method\": \"RNA-protein binding assay, SERCA2 protein stability assay, SERCA2 activity measurement, AMPK pathway analysis, in vitro and in vivo skeletal muscle models\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct binding shown with functional consequence, but single lab with limited mechanistic depth on AMPK pathway\",\n      \"pmids\": [\"35024244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SERCA2 inhibition by dapagliflozin's upstream target (XO-mediated SERCA2 oxidation and inactivation) drives cytoplasmic calcium overload, CaMKII activation, and cofilin phosphorylation leading to F-actin depolymerization in endothelial cells during ischemia-reperfusion; the beneficial effects of DAPA were largely prevented in SERCA2-knockout mice.\",\n      \"method\": \"SERCA2-knockout mice in IRI model, human coronary artery endothelial cells in H/R model, XO activity assay, SERCA2 oxidation measurement, Ca2+ imaging, CaMKII and cofilin phosphorylation assays\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO mice confirm SERCA2 centrality; pathway placement by pharmacological and genetic epistasis\",\n      \"pmids\": [\"35836807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"COX-2/PGE2 signaling downregulates ATP2A2/SERCA2 expression in keratinocytes; UVB-induced COX-2 upregulation suppresses ATP2A2 transcription and SERCA2 protein, and COX-2 inhibition (siRNA or celecoxib) rescues UVB-mediated suppression of SERCA2.\",\n      \"method\": \"COX-2 siRNA knockdown, celecoxib treatment, PGE2 addition, quantitative RT-PCR, Western blotting, luciferase reporter assay in keratinocytes\",\n      \"journal\": \"The British journal of dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA plus pharmacological approach with reporter assay; single lab\",\n      \"pmids\": [\"22413864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cardiac troponin I (cTnI) translocates to the nucleus in cardiomyocytes and binds to the Atp2a2 promoter region (-239 to -889 bp) at a 'CCAT' motif, positively regulating SERCA2 transcription; cTnI gain/loss causes dose-dependent increase/decrease in SERCA2 mRNA and protein.\",\n      \"method\": \"ChIP-sequencing, luciferase reporter assay, cTnI overexpression/siRNA knockdown in cardiomyocytes, Western blotting, Ca2+ transient measurement\",\n      \"journal\": \"Genes & diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq plus reporter assay with gain and loss of function; single lab\",\n      \"pmids\": [\"36157491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The SERCA2 C674S substitution (mimicking oxidative inactivation) activates the IRE1α/XBP1s ER stress pathway in pulmonary artery smooth muscle cells, accelerating cell cycle and proliferation to drive pulmonary vascular remodeling; IRE1α/XBP1s inhibition reverses these effects.\",\n      \"method\": \"SERCA2 C674S knock-in mice (SKI), IRE1α/XBP1s activity assays, cell proliferation/cell cycle analysis, pharmacological IRE1α/XBP1s inhibition, histological analysis of pulmonary vasculature\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — site-specific knock-in with pharmacological pathway dissection; single lab\",\n      \"pmids\": [\"35646520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SERCA2 interacts with LC3B via an LIR motif, facilitating WIPI2-independent autophagosome formation to induce autophagy in triple-negative breast cancer cells; autophagy-mediated SERCA2 degradation triggers Ca2+/CaMKK/CREB-1-dependent feedback transcriptional upregulation of SERCA2.\",\n      \"method\": \"Co-immunoprecipitation (SERCA2-LC3B), LIR motif identification, WIPI2 knockdown, Ca2+ measurement, CaMKK/CREB-1 pathway analysis, in vitro and in vivo TNBC models\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus mechanistic pathway analysis; single lab\",\n      \"pmids\": [\"36561988\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ATP2A2 encodes SERCA2, a sarco/endoplasmic reticulum Ca2+-ATPase that actively pumps Ca2+ from the cytosol into the ER/SR lumen; its activity is regulated by direct protein interactions (inhibited by phospholamban/calumenin/PDE3A, activated or anchored by AKAP18δ, phosphorylated by JNK2 at activating sites and inhibited by S663 phosphorylation), by redox modification of Cys674 (oxidation inactivates the pump and triggers downstream ER stress, NFAT/NF-κB, and IRE1α/XBP1s signaling), by post-translational modifications including O-GlcNAcylation and TG2-mediated serotonylation, and by transcriptional regulation via NFAT/calcineurin, TFAM/TFB2M, ERK/NF-κB, and cTnI; haploinsufficiency causes Darier disease through impaired keratinocyte Ca2+ homeostasis and epidermal adhesion/differentiation, and impairs cardiac contractility, β-cell function, and neuronal Ca2+ clearance.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"Molecular cloning of human kidney cDNAs revealed that the cardiac Ca2+-ATPase (ATP2A2/SERCA2) gene produces two alternatively spliced products: SERCA2a (identical to cardiac muscle Ca2+-ATPase) and SERCA2b (with the carboxyl-terminal 4 amino acids replaced by an extended 49-amino-acid sequence), with SERCA2b being the most abundant isoform in non-muscle tissues.\",\n      \"method\": \"cDNA cloning, Southern blotting, sequencing, and immunological characterization of microsomal fractions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with structural validation; foundational paper with 332 citations\",\n      \"pmids\": [\"2844796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Co-expression of SERCA2 with phospholamban in COS-1 cells demonstrated that phospholamban directly inhibits SERCA2 by lowering its Ca2+ affinity, establishing functional interaction between the two proteins.\",\n      \"method\": \"Transient transfection of COS-1 cells, Ca2+-transport assays in microsomes\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted functional interaction in heterologous expression system; replicated across multiple subsequent studies\",\n      \"pmids\": [\"2146166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The relative ratio of phospholamban to SERCA2 is a critical determinant of myocardial contractility; atrial muscles with a 4.2-fold lower phospholamban:SERCA2 ratio exhibit threefold faster contraction/relaxation rates than ventricular muscles, and phospholamban knockout hearts show enhanced contractility, demonstrating that phospholamban:SERCA2 stoichiometry directly regulates pump-dependent Ca2+ handling.\",\n      \"method\": \"Comparison of atrial vs. ventricular contractile parameters; phospholamban knockout mouse hearts; isolated work-performing heart preparations\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout + functional cardiac measurements; replicated across two experimental comparisons\",\n      \"pmids\": [\"9202840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Loss-of-function mutations in ATP2A2 (encoding SERCA2) cause Darier disease, demonstrating that SERCA2-mediated Ca2+ signaling is essential for keratinocyte cell-to-cell adhesion and differentiation. Thirteen mutations including frameshift deletions, splice-site mutations, and missense mutations in functional domains were identified.\",\n      \"method\": \"Mutation screening of ATP2A2 in Darier disease families; identification of 13 mutations in functional domains\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined cellular phenotype (acantholysis, abnormal keratinization); foundational paper with 576 citations\",\n      \"pmids\": [\"10080178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Heterozygous null mutation in the SERCA2 gene reduces SERCA2 mRNA by ~45%, protein and maximal Ca2+ uptake velocity by ~35%, and impairs cardiac contractility and relaxation, demonstrating that two functional copies of SERCA2 are required for normal cardiac Ca2+ sequestration and function.\",\n      \"method\": \"Gene targeting in mice; RNase protection, Western blotting, biochemical Ca2+ uptake assays, in vivo cardiovascular pressure measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic knockout with multiple orthogonal biochemical and functional measurements; 213 citations\",\n      \"pmids\": [\"9891028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Gene transfer of SERCA2a into failing human cardiomyocytes restores pump activity, increases contraction and relaxation velocity, decreases diastolic Ca2+, increases systolic Ca2+, and normalizes the frequency response, establishing that SERCA2a deficiency directly underlies contractile dysfunction in heart failure.\",\n      \"method\": \"Adenoviral gene transfer into isolated human failing cardiomyocytes; Ca2+ imaging, contractility measurements\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct gain-of-function rescue experiment in human cells with functional readouts; 386 citations\",\n      \"pmids\": [\"10587333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Disruption of one SERCA2 allele in mice reduces SR Ca2+ stores and Ca2+ release by ~30–60%, decreases myocyte shortening/relengthening rates by ~40%, and triggers compensatory reductions in phospholamban (by ~40%) with increased basal phosphorylation of PLB at Ser-16 and Thr-17 (~2-fold), along with upregulation of the Na+-Ca2+ exchanger, revealing adaptive mechanisms that partially compensate for reduced SERCA2 levels.\",\n      \"method\": \"SERCA2 heterozygous knockout mice; confocal Ca2+ imaging, myocyte contractility measurements, Western blotting, electrophysiology\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with multiple orthogonal functional and biochemical readouts; 107 citations\",\n      \"pmids\": [\"10970890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Somatic (mosaic) mutations in ATP2A2 cause segmental Darier disease following Blaschko's lines, confirming that postzygotic ATP2A2 mutations restricted to affected skin are sufficient to produce acantholytic dyskeratosis.\",\n      \"method\": \"Mutation analysis of affected skin vs. unaffected skin and leukocytes; identification of nonsense (Y894X) and missense (G769R) mutations present only in affected tissue\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct genotype-tissue comparison establishing somatic mosaicism; 108 citations\",\n      \"pmids\": [\"11121153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Haploinsufficiency of Atp2a2 (SERCA2) predisposes mice to squamous cell tumors of the forestomach, esophagus, oral mucosa, tongue, and skin, with 13/14 heterozygous mice developing tumors versus none in wild-type controls, establishing that perturbation of Ca2+ homeostasis via SERCA2 reduction can serve as a primary initiating event in squamous cell carcinogenesis.\",\n      \"method\": \"Aged Atp2a2+/- mice; histopathology, Western blot analysis of SERCA2 in affected tissues\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with clear tumor phenotype and molecular confirmation; 91 citations\",\n      \"pmids\": [\"11389134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In SERCA2+/- mice, the shorter Ca2+ transient evoked by agonist stimulation is due to upregulation of specific plasma membrane Ca2+ pump isoforms; Ca2+ oscillation frequency is reduced ~50%, but agonist-stimulated exocytosis is preserved through compensatory increases in Ca2+ sensitivity of exocytosis mediated by altered levels of Ca2+ sensors synaptotagmins I and III.\",\n      \"method\": \"SERCA2+/- mouse model; Ca2+ imaging, exocytosis assays, Western blotting of synaptotagmin isoforms\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with multiple orthogonal functional assays revealing specific adaptive mechanisms; 60 citations\",\n      \"pmids\": [\"11387203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"S-Glutathiolation of SERCA2 at Cys674 by NO-derived peroxynitrite directly activates SERCA Ca2+-uptake activity and mediates arterial relaxation; mutation of Cys674 to serine abolishes this activation, and irreversible oxidation of Cys674 to sulfonic acid in atherosclerosis prevents NO-dependent SERCA activation and arterial relaxation.\",\n      \"method\": \"Purified SERCA reconstituted in phospholipid vesicles; site-directed mutagenesis (C674S); Ca2+-uptake assays; mass spectrometry of oxidized Cys674 in atherosclerotic tissue\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution + mutagenesis + disease tissue validation; 541 citations\",\n      \"pmids\": [\"15489859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Atp2a2 haploinsufficiency causes squamous cell tumorigenesis via a novel mechanism not involving loss of heterozygosity (wild-type allele retained in tumors), without ras mutations, but with upregulated K-ras expression, establishing a cancer susceptibility mode based on global change in tumorigenic potential of keratinized epithelium.\",\n      \"method\": \"Laser capture microdissection of tumor cells; PCR for wild-type allele; ras mutation analysis; immunohistochemistry; Western blot; p53 analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — molecular dissection of tumor mechanism in genetic model with multiple analyses; 59 citations\",\n      \"pmids\": [\"16204033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Calumenin, a multiple EF-hand Ca2+-binding protein located in the cardiac SR lumen, directly interacts with SERCA2 and inhibits SERCA2-mediated Ca2+ uptake; the interaction is favored in the E1 state of SERCA2, and the binding regions are residues 132-222 of calumenin and 853-892 of SERCA2 luminal loop L4.\",\n      \"method\": \"Co-immunoprecipitation; GST-pulldown with calumenin deletion fragments and SERCA2 luminal domains; oxalate-supported Ca2+ uptake assays; calumenin knockdown in HL-1 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding domain mapping by GST-pulldown + functional Ca2+ uptake assays + cellular knockdown; 52 citations\",\n      \"pmids\": [\"19740751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mitochondrial transcription factors TFAM and TFB2M bind to the -122 to -114 nt region of the Serca2 gene promoter in rat neonatal cardiomyocytes (demonstrated by ChIP and fluorescence correlation spectroscopy), and their overexpression prevents stress-induced decreases in SERCA2a mRNA, revealing that these factors coordinate transcription of both mitochondrial metabolic genes and the SERCA2 gene.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); fluorescence correlation spectroscopy; promoter mutation analysis; adenoviral overexpression; rat myocardial infarction model\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding demonstrated by ChIP + mutagenesis + in vivo correlation; 45 citations\",\n      \"pmids\": [\"21113058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SERCA2a is SUMOylated at lysines 480 and 585, and this SUMOylation is essential for maintaining SERCA2a ATPase activity and stability; SUMO1 levels and SERCA2a SUMOylation are reduced in failing hearts, and AAV-mediated SUMO1 restoration improves SERCA2a function and cardiac performance comparably to SERCA2a gene delivery.\",\n      \"method\": \"Site-directed mutagenesis of K480 and K585; adeno-associated virus gene delivery; in vitro ATPase assays; cardiomyocyte Ca2+ decay measurements; pressure-overload mouse model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis identifying specific SUMOylation sites + in vivo rescue experiments; 320 citations\",\n      \"pmids\": [\"21900893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SERCA2 protein aggregation is triggered by Darier disease-associated missense mutations; these mutant proteins are less soluble, aggregate, become polyubiquitinated, and when transduced into primary keratinocytes, elicit ER stress and induce apoptosis and cell detachment, establishing a gain-of-toxic-function pathogenic mechanism distinct from simple haploinsufficiency.\",\n      \"method\": \"Expression of DD-associated SERCA2 mutants; solubility assays; polyubiquitination assays; adenoviral transduction into primary human keratinocytes; ER stress markers; apoptosis assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic analysis of multiple DD mutants with orthogonal biochemical and cellular readouts; 33 citations\",\n      \"pmids\": [\"22045735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SERCA2b-controlled ER Ca2+ sequestration regulates keratinocyte adhesion and differentiation via the sphingolipid signaling pathway: SERCA2b inhibition increases sphingosine levels and decreases sphingosine kinase (SPHK1) expression, and inhibiting sphingolipid lyase rescues defects in keratinocyte differentiation, E-cadherin localization, and desmoplakin translocation caused by SERCA2 inhibition.\",\n      \"method\": \"SERCA2b inhibition with thapsigargin and siRNA; sphingolipid pathway analysis; rescue experiments with sphingolipid lyase inhibitor; immunofluorescence of E-cadherin and desmoplakin\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway epistasis established by pharmacological and genetic perturbations with specific molecular readouts; 34 citations\",\n      \"pmids\": [\"22277942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Phosphodiesterase 3A1 (PDE3A1) directly interacts with SERCA2 in human cardiac SR; phosphorylation of PDE3A1 by PKA at Ser-292/Ser-293 (unique to PDE3A1) promotes its incorporation into SERCA2/AKAP18 signalosomes; PDE3A co-immunoprecipitates with SERCA2, cav3, PKARII, PP2A, and AKAP18; and deletion of the PDE3A1 N-terminus blocks SERCA2 interaction, placing PDE3A1 as a regulator of a discrete cAMP pool controlling PLB phosphorylation and SERCA2 activity.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins from human SR; gel filtration chromatography; recombinant protein co-IP; deletion mutants; site-directed mutagenesis; PKA phosphorylation assays; immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal co-IP + mutagenesis + recombinant protein interaction mapping + functional assays; 83 citations\",\n      \"pmids\": [\"25593322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SERCA2 deficiency in pancreatic beta cells impairs ER Ca2+ homeostasis, glucose-induced Ca2+ mobilization, insulin secretion, proinsulin processing, and beta-cell mass under high-fat diet conditions; pharmacological SERCA2 activation rescues tunicamycin-induced beta-cell death, establishing SERCA2 as critical for the beta-cell compensatory response to obesity.\",\n      \"method\": \"SERCA2 heterozygous mice on high-fat diet; Ca2+ imaging in islets; insulin secretion assays; beta-cell mass quantification; ER stress markers; SERCA2 activator treatment\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model + pharmacological rescue with multiple functional readouts; 74 citations\",\n      \"pmids\": [\"27489309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"JNK2 (but not JNK1) directly associates with and phosphorylates SERCA2, increasing SERCA2 ATPase activity (maximal rate without altering Ca2+ affinity) and SR Ca2+ content in a CaMKII-independent manner, thereby exacerbating an arrhythmic SR Ca2+ leak-load relationship in aged and alcohol-exposed hearts.\",\n      \"method\": \"Confocal Ca2+ imaging; biochemical SERCA2 ATPase activity assays; co-immunoprecipitation; dual Ca2+/voltage optical mapping in intact hearts; JNK2-specific inhibition; CaMKII inhibitor controls\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biochemical phosphorylation + ATPase activity assay + co-IP + functional imaging; 41 citations\",\n      \"pmids\": [\"33334123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"O-GlcNAcylation of SERCA2 in pancreatic beta cells, mediated by OGT, is required for lipid-stimulated insulin hypersecretion; SERCA2 was identified as a beta-cell O-GlcNAcylated protein in mice and humans, and pharmacological SERCA2 activation rescues impaired palmitate-stimulated insulin secretion in OGT-deficient islets.\",\n      \"method\": \"OGT-specific beta-cell knockout mice; in vivo and in vitro insulin secretion assays; identification of O-GlcNAcylated SERCA2 by proteomic approaches; pharmacological SERCA2 activation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic model + pharmacological rescue; O-GlcNAcylation of SERCA2 identified but specific sites not mapped by mutagenesis\",\n      \"pmids\": [\"32375037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TG2-mediated serotonylation of SERCA2 inhibits SERCA2 activity, leading to increased cytosolic Ca2+ and store-operated Ca2+ entry via TRPC6; hypoxia enhances TG2 expression and activity promoting SERCA2 serotonylation both in vitro and in vivo, and vascular smooth muscle-specific Tgm2 knockout prevents hypoxia-induced pulmonary vascular remodeling.\",\n      \"method\": \"Co-immunoprecipitation; TG2 gene silencing/overexpression; SERCA2 activity assays; Fluo-4AM Ca2+ measurements; tissue-specific conditional TG2 knockout mice; hemodynamic measurements\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP + functional assays + genetic model; serotonylation site not confirmed by mutagenesis\",\n      \"pmids\": [\"32116663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Inactivation of SERCA2 Cys674 (C674S knock-in, representing irreversible oxidation) causes intracellular Ca2+ accumulation that activates calcineurin, promoting nuclear translocation of NFAT and NF-κB, resulting in smooth muscle cell phenotypic modulation and acceleration of angiotensin II-induced aortic aneurysm.\",\n      \"method\": \"SERCA2 C674S heterozygous knock-in mice; aortic aneurysm model; calcineurin inhibition; NFAT/NFκB nuclear translocation assays; SMC phenotypic marker Western blots\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knock-in mouse model with defined molecular mechanism and pathway placement; 21 citations\",\n      \"pmids\": [\"32035136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Inactivation of SERCA2 Cys674 in the kidney (C674S knock-in mice) promotes hypertension by inducing ER stress and upregulating soluble epoxide hydrolase (sEH), which together suppress dopamine D1 receptor expression, impairing Na+/K+-ATPase regulation and sodium excretion.\",\n      \"method\": \"SERCA2 C674S heterozygous knock-in mice; blood pressure measurement; urine sodium/volume analysis; ER stress marker Western blots; D1 receptor expression; Na+/K+-ATPase activity assays\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knock-in model with pathway inhibitor experiments establishing mechanism; single study\",\n      \"pmids\": [\"31758704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AKAP18δ anchors CaMKIIδ at SERCA2-PLN and RYR via two distinct regions: an N-terminal region (AKAP18δ-N) inhibits CaMKIIδ by binding a region homologous to CaMKII inhibitor peptide and the Thr17-PLN region, while a C-terminal region (AKAP18δ-C) activates CaMKIIδ by lowering the Ca2+ threshold for kinase activation and inducing CaM trapping; AKAP18δ-C facilitates faster Ca2+ reuptake by SERCA2.\",\n      \"method\": \"Peptide arrays; cell-permeant peptide technology; immunoprecipitations; pull-downs; FRET-based CaMKII activity assays; SR vesicle fluorescence imaging; surface plasmon resonance; AAV injection in mice\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including SPR, FRET, peptide mapping, and in vivo validation; 40 citations\",\n      \"pmids\": [\"34814703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Brain-specific heterozygous loss of Atp2a2 (SERCA2) in mice causes slower cytosolic Ca2+ decay after neuronal depolarization (due to decreased ER Ca2+ uptake), behavioral abnormalities including altered novelty responses and impaired fear memory, and elevated extracellular dopamine in the nucleus accumbens, establishing that SERCA2 haploinsufficiency in brain produces a hyperdopaminergic state.\",\n      \"method\": \"Brain-specific conditional Atp2a2 heterozygous knockout mice; ER Ca2+ uptake assays; neuronal Ca2+ imaging after depolarization; behavioral testing; in vivo microdialysis for dopamine\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional genetic model with biochemical, Ca2+ imaging, behavioral, and in vivo neurochemical readouts; 25 citations\",\n      \"pmids\": [\"34104969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Sigma-1 receptor (Sigmar1) interacts with SERCA2 (with Q615 as the critical binding residue) and promotes SERCA2 degradation through Hrd1/Sel1L-dependent ER-associated degradation (ERAD), with ubiquitination of SERCA2 at K460 and K541 targeting it for proteasomal degradation; this mechanism attenuates osteoclastogenesis.\",\n      \"method\": \"IP-mass spectrometry; co-immunoprecipitation; mutagenesis of SERCA2 Q615 and K460/K541; ERAD inhibition; proteasome inhibitor experiments; Sigmar1 knockout and overexpression in mice\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — IP-MS + co-IP + mutagenesis identifying specific interaction and ubiquitination sites + genetic models; 31 citations\",\n      \"pmids\": [\"35611810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SERCA2 oxidation and inactivation by xanthine oxidase (XO) during cardiac ischemia/reperfusion leads to cytoplasmic Ca2+ overload, CaMKII activation, and cofilin phosphorylation causing F-actin depolymerization and endothelial dysfunction; SGLT2 inhibitor dapagliflozin inhibits this XO-SERCA2-CaMKII-cofilin pathway, and its protective effects are lost in SERCA2-knockout mice.\",\n      \"method\": \"SERCA2 knockout mice subjected to ischemia/reperfusion; human coronary artery endothelial cells with hypoxia/reoxygenation; XO activity measurements; SERCA2 oxidation assays; CaMKII and cofilin phosphorylation; endothelial function assays\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout validation + pathway dissection with multiple orthogonal assays in vivo and in vitro; 99 citations\",\n      \"pmids\": [\"35836807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SERCA2 interacts with LC3B via an LIR motif to facilitate WIPI2-independent autophagosome formation, promoting autophagy in triple-negative breast cancer cells; autophagy-mediated SERCA2 degradation induces SERCA2 transcriptional upregulation through a Ca2+/CaMKK/CREB-1 feedback loop.\",\n      \"method\": \"Co-immunoprecipitation of SERCA2 with LC3B; LIR motif identification; autophagy flux assays; Ca2+ imaging; CaMKK inhibition; CREB-1 reporter assays; in vitro and in vivo tumor models\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP + pathway inhibition experiments; mechanistic details of LIR-mediated interaction need structural confirmation\",\n      \"pmids\": [\"36561988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SERCA2 phosphorylation at serine 663 is increased in ischemic human and mouse hearts; preventing serine 663 phosphorylation significantly increases SERCA2 activity and protects against cell death by counteracting cytosolic and mitochondrial Ca2+ overload, establishing serine 663 as a pathophysiological regulatory site of SERCA2 activity.\",\n      \"method\": \"Phosphoproteomic analysis of ischemic human hearts; mutagenesis preventing S663 phosphorylation; SERCA2 ATPase activity assays; Ca2+ homeostasis measurements in human cell lines; infarct size analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — clinical tissue validation + mutagenesis + functional enzyme assays; 32 citations\",\n      \"pmids\": [\"37291092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MFN2 interacts with ER-embedded SERCA2 at mitochondria-ER contact sites (MAMs) to enhance SERCA2 ER Ca2+ retrieval activity, facilitating mitochondrial Ca2+ influx required for efficient mitochondrial metabolism in CD8+ T cells while preventing excessive mitochondrial Ca2+ accumulation and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of MFN2 and SERCA2; Mfn2 genetic ablation in CD8+ T cells; mitochondria-ER contact site imaging; mitochondrial Ca2+ measurements; metabolic assays; tumor models\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP establishing direct interaction + genetic ablation + functional metabolic readouts; 75 citations\",\n      \"pmids\": [\"37738362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SERCA2 deficiency in beta cells impairs spatial regulation of prohormone trafficking, causing mis-location of proinsulin and proPC2 to the ERGIC/cis-Golgi, and decreases expression of active forms of proinsulin processing enzymes PC1/3 and PC2, linking ER Ca2+ depletion to defective insulin maturation.\",\n      \"method\": \"Beta-cell-specific SERCA2 knockout mice; RNA-seq; Ca2+ imaging; proinsulin processing assays; immunofluorescence of proinsulin and proPC2 localization; INS-1 SERCA2-deficient cell line\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional beta-cell knockout with detailed mechanistic analysis of processing enzyme localization and activity; 15 citations\",\n      \"pmids\": [\"37537395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PDE3A directly binds to amino acids 169-216 within the actuator domain of SERCA2 via PDE3A amino acids 277-402, and this interaction inhibits SERCA2 activity independently of PDE3A catalytic activity; disruption of the SERCA2/PDE3A interaction by disruptor peptides increases SERCA2 activity in normal and failing cardiomyocytes and reduces cardiac mortality after aortic banding in mice.\",\n      \"method\": \"2-color dSTORM; proximity ligation assay; co-immunoprecipitation; peptide arrays; surface plasmon resonance; HEK293 vesicle Ca2+ uptake assays; AAV9 gene delivery in mice; serial echocardiography; cardiac MRI\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding domain mapping by multiple methods + functional ATPase assays + in vivo preclinical trials; 19 citations\",\n      \"pmids\": [\"36876489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"An E box/AT-rich element at -1115 bp is critical for muscle-specific enhancer activity of the SERCA2 gene promoter; gel mobility shift studies show this element specifically binds a protein induced during myogenesis, and it acts together with CArG and MCAT elements to regulate SERCA2 transcription.\",\n      \"method\": \"Deletion analysis; reporter gene assays in Sol8 myotubes; gel mobility shift assays; mutagenesis of cis-acting elements\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — deletion analysis + EMSA + mutagenesis; specific transcription factor identity not fully established\",\n      \"pmids\": [\"9461473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human SERCA2 gene promoter contains a TATA-like box, CAAT-box, three Sp1 sites, a CACCC-box, OTF-1 binding sequence, and two putative thyroid response elements; sequences from -263 to +170 bp are necessary for maximal transcriptional activity and sequences from -125 to +170 bp are essential for basal activity in cardiomyocytes and myotubes.\",\n      \"method\": \"Genomic cloning; 5' deletion reporter constructs; transfection into neonatal rat cardiomyocytes and C2C12 myotubes; luciferase assays\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic promoter deletion analysis with functional reporter assays; 21 citations\",\n      \"pmids\": [\"8930809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cardiac troponin I (cTnI) translocates to the nucleus in cardiomyocytes and binds to the Atp2a2 promoter in the -239 to -889 region at a 'CCAT' motif, positively regulating SERCA2a expression; TNNI3 gain/loss causes dose-dependent Atp2a2 mRNA and protein changes, and increasing cTnI increases SERCA2a promoter activity in luciferase assays.\",\n      \"method\": \"ChIP-sequencing; luciferase reporter assays; TNNI3 siRNA and overexpression; Western blotting; Ca2+ transient measurements\",\n      \"journal\": \"Genes & diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq + luciferase reporter + gene manipulation; single study with moderate functional follow-up\",\n      \"pmids\": [\"36157491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Substitution of SERCA2 Cys674 (C674S knock-in) activates the IRE1α/XBP1s ER stress pathway in pulmonary artery smooth muscle cells, accelerating cell cycle and proliferation, leading to pulmonary vascular remodeling resembling pulmonary hypertension; this is reversed by IRE1α/XBP1s pathway inhibitor 4μ8C.\",\n      \"method\": \"SERCA2 C674S heterozygous knock-in mice; IRE1α/XBP1s pathway analysis; cell cycle assays; PASMC proliferation assays; right ventricular systolic pressure measurements\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knock-in + pathway inhibitor rescue; mechanistic link between C674 oxidation and IRE1α activation not fully biochemically established\",\n      \"pmids\": [\"35646520\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ATP2A2 (SERCA2) encodes a P-type Ca2+-ATPase that pumps cytosolic Ca2+ into the SR/ER lumen; its two major isoforms (SERCA2a in cardiac/slow-twitch muscle, SERCA2b ubiquitously expressed) are regulated by multiple direct protein interactions and post-translational modifications including: inhibition by phospholamban (relieved by PLB phosphorylation), activation by S-glutathiolation at Cys674 by NO/peroxynitrite, SUMOylation at Lys480/Lys585 that maintains ATPase stability and activity, phosphorylation at Ser663 (inhibitory) and by JNK2 (activating), O-GlcNAcylation, serotonylation by TG2 (inhibitory), and inhibitory binding by calumenin and PDE3A1 (whose phosphorylation at Ser292/293 by PKA promotes its incorporation into a SERCA2/AKAP18 signalosome); SERCA2 activity is anchored and regulated at the SR by AKAP18δ-CaMKIIδ complexes, and its transcription is controlled by NFAT/calcineurin, TFAM/TFB2M, ERK/NF-κB, and cTnI; haploinsufficiency causes Darier disease (acantholysis and dyskeratosis), squamous cell tumors, and a hyperdopaminergic neuropsychiatric phenotype, while SERCA2 reduction in failing hearts impairs Ca2+ homeostasis and contractility, establishing it as a central regulator of Ca2+ cycling in multiple cell types.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ATP2A2 encodes SERCA2, the principal sarco/endoplasmic reticulum Ca²⁺-ATPase that actively transports cytosolic Ca²⁺ into the ER/SR lumen, thereby governing intracellular Ca²⁺ homeostasis across diverse cell types including cardiomyocytes, keratinocytes, pancreatic β cells, neurons, and smooth muscle cells. SERCA2 pump activity is inhibited by phospholamban (which reduces Ca²⁺ affinity), calumenin (which binds the L4 luminal loop in the E1 state), PDE3A1 (which directly contacts the actuator domain independently of its catalytic function), serotonylation by transglutaminase 2, and phosphorylation at Ser663, while it is stimulated by JNK2-mediated phosphorylation and scaffolded by AKAP18δ, which dually regulates CaMKII activity at the SERCA2–phospholamban complex [PMID:2146166, PMID:19740751, PMID:36876489, PMID:33334123, PMID:34814703, PMID:37291092, PMID:32116663]. Heterozygous loss-of-function mutations in ATP2A2 cause Darier disease through ER stress, protein aggregation, and disrupted keratinocyte adhesion and differentiation, while haploinsufficiency also impairs cardiac contractility, β-cell insulin processing, and neuronal Ca²⁺ clearance [PMID:10080178, PMID:9891028, PMID:37537395, PMID:34104969]. Oxidative inactivation of the redox-sensitive Cys674 residue triggers ER stress signaling through IRE1α/XBP1s and calcineurin/NFAT/NF-κB pathways, linking SERCA2 dysfunction to vascular remodeling and hypertension [PMID:31758704, PMID:32035136, PMID:35646520].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Establishing that SERCA2 pump activity is directly regulated by protein–protein interaction with phospholamban answered how cardiac Ca²⁺ reuptake is tuned at the molecular level.\",\n      \"evidence\": \"Co-expression of SERCA2 and phospholamban cDNAs in COS-1 cells with microsomal Ca²⁺ transport assay\",\n      \"pmids\": [\"2146166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the phospholamban–SERCA2 interaction not resolved in this study\", \"Phosphorylation-dependent relief of inhibition not yet demonstrated\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating that the phospholamban:SERCA2 stoichiometric ratio determines contractile kinetics established quantitative regulation of SERCA2 as a primary determinant of myocardial performance.\",\n      \"evidence\": \"Comparison of atrial vs. ventricular muscle and phospholamban-knockout mouse hearts\",\n      \"pmids\": [\"9202840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ratio shifts occur dynamically in disease states was not addressed\", \"Contributions of other regulators (e.g. sarcolipin) not isolated\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of muscle-specific cis-regulatory elements (E box/AT-rich, CArG, MCAT) in the SERCA2 promoter explained tissue-restricted transcription.\",\n      \"evidence\": \"Deletion/mutagenesis and gel-shift assays with reporter transfection in Sol8 myotubes\",\n      \"pmids\": [\"9461473\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the muscle-induced trans-acting factor not determined\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of ATP2A2 mutations in Darier disease families established that SERCA2 haploinsufficiency disrupts keratinocyte Ca²⁺ signaling, adhesion, and differentiation, linking pump dysfunction to human disease.\",\n      \"evidence\": \"Mutation screening in multiple Darier disease families identifying 13 mutations across functional domains\",\n      \"pmids\": [\"10080178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype–phenotype correlation across mutation classes not fully resolved\", \"Dominant-negative vs. haploinsufficiency mechanism not distinguished\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Heterozygous SERCA2 knockout mice showed that loss of one allele reduces protein by ~35% and impairs cardiac contractility, establishing dosage sensitivity in the heart.\",\n      \"evidence\": \"Gene-targeted heterozygous knockout mice with hemodynamic measurements, Ca²⁺ uptake assays, and protein quantification\",\n      \"pmids\": [\"9891028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term progression to heart failure not characterized\", \"Compensatory mechanisms not fully catalogued\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that SERCA2 haploinsufficiency triggers compensatory phospholamban phosphorylation and Na⁺/Ca²⁺ exchanger upregulation revealed the homeostatic network that partially buffers reduced pump activity.\",\n      \"evidence\": \"Ca²⁺ imaging, immunoblotting for PLB phosphorylation, and NCX current measurements in SERCA2+/− cardiomyocytes\",\n      \"pmids\": [\"10970890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether compensatory mechanisms are sufficient long-term is unknown\", \"Signaling pathways driving PLB hyperphosphorylation not identified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The finding that SERCA2 haploinsufficient mice develop squamous cell tumors without loss of heterozygosity established SERCA2 as a haploinsufficient tumor suppressor, broadening its role beyond contractility.\",\n      \"evidence\": \"Atp2a2+/− mice with tumor characterization and LOH exclusion\",\n      \"pmids\": [\"11389134\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking Ca²⁺ dysregulation to tumorigenesis not delineated\", \"Relevance to human squamous cancers not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapping the calumenin–SERCA2 interaction to specific domains (calumenin 132–222 and SERCA2 luminal loop L4) revealed a luminal inhibitory mechanism distinct from cytoplasmic phospholamban regulation.\",\n      \"evidence\": \"Reciprocal Co-IP, GST-pulldown with deletion fragments, and Ca²⁺ uptake assays in calumenin-knockdown HL-1 cells\",\n      \"pmids\": [\"19740751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of the E1-state selectivity not resolved\", \"Physiological contexts where calumenin dominates regulation unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that calcineurin/NFAT and mitochondrial transcription factors (TFAM/TFB2M) regulate SERCA2 transcription established Ca²⁺-dependent and metabolic feedback loops controlling pump expression.\",\n      \"evidence\": \"siRNA/pharmacological inhibition of calcineurin-NFAT and ChIP for TFAM/TFB2M at the Serca2 promoter in neonatal rat cardiomyocytes\",\n      \"pmids\": [\"21057045\", \"21113058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NFAT binding to SERCA2 promoter in vivo not confirmed by ChIP\", \"TFAM/TFB2M mechanism in non-cardiac tissues unknown\", \"Both from single laboratories\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showing that Darier disease SERCA2 mutants aggregate, are polyubiquitinated, and induce ER stress and apoptosis in primary keratinocytes distinguished dominant-negative proteotoxic effects from simple haploinsufficiency.\",\n      \"evidence\": \"Systematic mutagenesis reproducing patient mutations, solubility/aggregation assays, and ER stress markers in primary human keratinocytes\",\n      \"pmids\": [\"22045735\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of proteotoxicity vs. loss-of-function not quantified in patient skin\", \"Single laboratory\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linking SERCA2 inhibition to sphingolipid dysregulation and impaired desmosome assembly explained how reduced ER Ca²⁺ disrupts epidermal differentiation beyond simple Ca²⁺ signaling.\",\n      \"evidence\": \"Thapsigargin/siRNA knockdown of SERCA2b in keratinocytes with sphingolipid pathway analysis and rescue by sphingosine lyase inhibition\",\n      \"pmids\": [\"22277942\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether sphingolipid changes occur in Darier patient skin not tested\", \"Single laboratory\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying ERK/NF-κB-mediated repression and epigenetic modifications (histone methylation, DNMT recruitment) at the Atp2a2 promoter during cardiac hypertrophy explained transcriptional SERCA2 downregulation in heart failure.\",\n      \"evidence\": \"ERK inhibition rescue, NF-κB activation experiments, and ChIP for histone marks at Atp2a2 promoter in TAC mouse model and neonatal cardiomyocytes\",\n      \"pmids\": [\"25008120\", \"25181347\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal role of specific histone marks not established by functional experiments\", \"Whether epigenetic changes are reversible therapeutically not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining PDE3A1 as a component of a SERCA2/AKAP18 signalosome, with PKA-regulated binding via its N-terminal phosphosites, revealed how local cAMP compartmentalization tunes SERCA2 activity in the cardiac SR.\",\n      \"evidence\": \"Gel filtration, Co-IP, recombinant interaction assay, and site-directed mutagenesis of PDE3A1 Ser-292/293\",\n      \"pmids\": [\"25593322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of PDE3A1 to local cAMP pool not measured\", \"Whether other PDE3A isoforms compensate is unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that SERCA2 deficiency in β cells impairs insulin secretion, ER Ca²⁺ stores, and β-cell mass extended SERCA2 function beyond excitable tissues to metabolic regulation.\",\n      \"evidence\": \"SERCA2 heterozygous mice on high-fat diet with glucose tolerance tests, Ca²⁺ imaging, and pharmacological SERCA2 activation rescue\",\n      \"pmids\": [\"27489309\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific SERCA2 isoform (2a vs. 2b) contribution in β cells not resolved\", \"Mechanism of β-cell mass reduction not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Multiple studies converged on Cys674 as a critical redox switch: C674S knock-in mice showed that oxidative inactivation of SERCA2 triggers ER stress, activates calcineurin/NFAT/NF-κB, and drives hypertension and vascular remodeling, establishing redox regulation of SERCA2 as a disease mechanism.\",\n      \"evidence\": \"SERCA2 C674S knock-in mice with blood pressure measurement, ER stress markers, NFAT/NF-κB translocation assays, and aortic aneurysm models\",\n      \"pmids\": [\"31758704\", \"32035136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which oxidants modify C674 in vivo not fully characterized\", \"Whether C674 modification is reversible therapeutically is untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of O-GlcNAcylation of SERCA2 in β cells and serotonylation by TG2 under hypoxia revealed two novel post-translational regulatory mechanisms that modulate pump activity in metabolic and vascular contexts.\",\n      \"evidence\": \"O-GlcNAc proteomics in mouse/human islets with OGT deletion rescue; TG2-mediated serotonylation by Co-IP and TG2 knockout mice\",\n      \"pmids\": [\"32375037\", \"32116663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific O-GlcNAcylation sites on SERCA2 not mapped\", \"Serotonylation sites not identified\", \"Both from single laboratories\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"JNK2 was identified as a direct SERCA2 kinase that enhances maximal pump rate independently of CaMKII, adding an isoform-specific kinase activator to the SERCA2 regulatory network.\",\n      \"evidence\": \"Co-IP, phosphorylation assays, JNK isoform-specific manipulation, CaMKII inhibition controls, and optical mapping in intact hearts\",\n      \"pmids\": [\"33334123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"JNK2 phosphorylation sites on SERCA2 not mapped\", \"Physiological stimuli that activate JNK2-SERCA2 axis not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"AKAP18δ was shown to scaffold CaMKIIδ at the SERCA2–PLN complex with dual regulatory regions (N-terminal inhibitory, C-terminal activating), explaining how a single scaffold can bidirectionally tune Ca²⁺ reuptake.\",\n      \"evidence\": \"Peptide arrays, SPR, FRET-based CaMKII activity assay, SR vesicle imaging, proximity ligation, and AAV injection in mice\",\n      \"pmids\": [\"34814703\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which physiological signals favor N- vs. C-terminal domain engagement unknown\", \"In vivo consequences of disrupting individual AKAP18δ domains not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Brain-specific SERCA2 haploinsufficiency prolonged neuronal Ca²⁺ transients and elevated extracellular dopamine, establishing a neuronal function for SERCA2 relevant to neuropsychiatric phenotypes in Darier disease.\",\n      \"evidence\": \"Brain-specific conditional knockout mice with Ca²⁺ decay imaging and in vivo microdialysis in nucleus accumbens\",\n      \"pmids\": [\"34104969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dopamine elevation explains neuropsychiatric comorbidity in Darier patients not established\", \"Other neurotransmitter systems not examined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that Sigma-1 receptor promotes SERCA2 ubiquitin-dependent degradation via Hrd1/Sel1L ERAD (targeting K460 and K541) identified a regulated turnover mechanism controlling SERCA2 protein levels.\",\n      \"evidence\": \"IP-MS, Co-IP, site-directed mutagenesis of SERCA2 Q615 and K460/K541, Sigmar1 KO/OE mice, ubiquitination assay\",\n      \"pmids\": [\"35611810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERAD-mediated degradation is altered in disease states unknown\", \"Contribution of other E3 ligases not assessed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mapping PDE3A binding to the SERCA2 actuator domain (aa 169–216) and showing that a competing peptide (OptF) rescues SERCA2 activity and reduces cardiac mortality provided a therapeutic proof-of-concept for disrupting inhibitory protein interactions.\",\n      \"evidence\": \"PLA, Co-IP, peptide arrays, SPR, STORM, functional vesicle assays, and two randomized preclinical trials with rAAV9 delivery (n=148 mice)\",\n      \"pmids\": [\"36876489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety and efficacy of OptF peptide unknown\", \"Whether PDE3A–SERCA2 interaction differs across heart failure etiologies not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that SERCA2 phosphorylation at Ser663 increases in ischemic hearts and that preventing this phosphorylation rescues pump activity and cell survival identified a targetable inhibitory phosphosite.\",\n      \"evidence\": \"Phosphosite identification in human ischemic tissue, S663A mutagenesis, SERCA2 activity assays, and Ca²⁺ measurements in human cell lines\",\n      \"pmids\": [\"37291092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for S663 phosphorylation not identified\", \"In vivo infarct size reduction in the S663A mutant not shown in large animal models\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"MFN2 interaction with ER-embedded SERCA2 at mitochondria–ER contacts showed that SERCA2 coordinates ER-to-mitochondrial Ca²⁺ transfer and metabolic fitness in CD8⁺ T cells, extending SERCA2 function to adaptive immunity.\",\n      \"evidence\": \"Co-IP of MFN2–SERCA2, Mfn2 and SERCA2 genetic ablation in CD8⁺ T cells, Ca²⁺ imaging, mitochondrial function assays\",\n      \"pmids\": [\"37738362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SERCA2–MFN2 interaction is direct or scaffolded not resolved\", \"Relevance to other immune cell types unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"β-cell-specific SERCA2 deletion revealed that ER Ca²⁺ is required for prohormone convertase activation and proinsulin trafficking through the ERGIC/cis-Golgi, mechanistically explaining impaired insulin maturation.\",\n      \"evidence\": \"β-cell-specific knockout mice, ER Ca²⁺ imaging, RNA-seq, immunofluorescence for proinsulin/proPC2/Golgi markers, human islet validation\",\n      \"pmids\": [\"37537395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER Ca²⁺ depletion affects other secretory cargoes beyond insulin not tested\", \"Therapeutic implications for type 2 diabetes not explored\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: (1) the full set of SERCA2 phosphorylation sites and their cognate kinases/phosphatases under physiological and pathological conditions; (2) the structural basis for how diverse regulators (PDE3A, calumenin, MFN2, Sigmar1) access distinct SERCA2 conformational states; (3) whether redox, glycosylation, and serotonylation modifications interact combinatorially; and (4) whether therapeutic targeting of specific inhibitory interactions (e.g., PDE3A, S663 phosphorylation) translates to clinical benefit.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No comprehensive SERCA2 PTM map integrating all modifications\", \"No high-resolution structure of SERCA2 in complex with PDE3A, calumenin, or MFN2\", \"Clinical translation of preclinical therapeutic strategies not demonstrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 1, 3, 4, 7, 10, 11, 12]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 3, 4, 27, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 7, 20, 21, 23, 25, 28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 3, 4, 7, 27, 28]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 9, 10, 15, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 5, 25]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [21, 22, 34]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [12, 18, 19, 20]}\n    ],\n    \"complexes\": [\n      \"SERCA2/phospholamban complex\",\n      \"SERCA2/AKAP18δ/CaMKIIδ signalosome\",\n      \"SERCA2/PDE3A1/AKAP18 signalosome\"\n    ],\n    \"partners\": [\n      \"PLN\",\n      \"PDE3A\",\n      \"AKAP7\",\n      \"CALU\",\n      \"SIGMAR1\",\n      \"MFN2\",\n      \"MAPK9\",\n      \"LC3B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ATP2A2 encodes SERCA2, a P-type Ca²⁺-ATPase that actively transports cytosolic Ca²⁺ into the sarcoplasmic/endoplasmic reticulum lumen, functioning as a master regulator of intracellular Ca²⁺ homeostasis across muscle and non-muscle cell types [PMID:2844796, PMID:9891028]. SERCA2 activity is tuned by an extensive network of direct regulators: inhibited by phospholamban (whose stoichiometric ratio to SERCA2 sets contractile kinetics), calumenin binding at luminal loop L4, PDE3A1 docking at the actuator domain, serotonylation by TG2, and phosphorylation at Ser663, while being activated by S-glutathiolation at Cys674, SUMOylation at Lys480/Lys585, JNK2-mediated phosphorylation, and O-GlcNAcylation [PMID:2146166, PMID:9202840, PMID:19740751, PMID:36876489, PMID:15489859, PMID:21900893, PMID:33334123, PMID:37291092]. Haploinsufficiency of ATP2A2 causes Darier disease through disrupted keratinocyte adhesion and differentiation, predisposes to squamous cell carcinogenesis, impairs cardiac contractility, disrupts pancreatic β-cell insulin processing, and produces a hyperdopaminergic neuropsychiatric phenotype [PMID:10080178, PMID:11389134, PMID:10587333, PMID:37537395, PMID:34104969]. SERCA2 is further integrated into supramolecular signaling complexes via AKAP18δ-CaMKIIδ scaffolding at the SR and MFN2-mediated coupling at mitochondria-ER contact sites, and its turnover is controlled by Sigmar1-dependent Hrd1/Sel1L ERAD [PMID:34814703, PMID:37738362, PMID:35611810].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Molecular cloning established that a single ATP2A2 gene produces two isoforms—cardiac SERCA2a and ubiquitous SERCA2b—through alternative splicing, resolving the molecular basis of tissue-specific Ca²⁺ pump expression.\",\n      \"evidence\": \"cDNA cloning and sequencing of human kidney SERCA2 transcripts with Southern blot and immunological validation\",\n      \"pmids\": [\"2844796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional differences between SERCA2a and SERCA2b catalytic properties not yet compared\", \"Regulatory elements governing isoform-specific splicing unknown\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Co-expression experiments demonstrated that phospholamban directly inhibits SERCA2 by lowering Ca²⁺ affinity, establishing the first regulatory partner of the pump and the principle that SERCA2 activity is modulated by protein–protein interaction.\",\n      \"evidence\": \"COS-1 cell co-transfection with Ca²⁺-transport assays in microsomes\",\n      \"pmids\": [\"2146166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of PLB–SERCA2 interaction unknown\", \"Whether the PLB:SERCA2 stoichiometry has physiological consequences untested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The physiological significance of PLB:SERCA2 stoichiometry was demonstrated by showing that chambers with lower PLB:SERCA2 ratios contract faster, and PLB knockout enhances contractility, proving that this ratio is a primary determinant of cardiac Ca²⁺ handling kinetics.\",\n      \"evidence\": \"Comparison of atrial vs. ventricular contractile parameters and PLB knockout mouse hearts\",\n      \"pmids\": [\"9202840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether stoichiometric regulation is dynamic under stress conditions unclear\", \"Other endogenous SERCA2 inhibitors not yet identified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Three convergent studies established SERCA2 as essential in vivo: loss-of-function mutations caused Darier disease in humans, heterozygous knockout impaired cardiac function in mice, and SERCA2a gene transfer rescued contractile dysfunction in failing human cardiomyocytes, linking pump deficiency to skin, cardiac, and disease phenotypes.\",\n      \"evidence\": \"Human mutation screening in Darier families; SERCA2+/− mouse cardiovascular measurements; adenoviral SERCA2a delivery to failing human cardiomyocytes with Ca²⁺ and contractility readouts\",\n      \"pmids\": [\"10080178\", \"9891028\", \"10587333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking ER Ca²⁺ depletion to keratinocyte acantholysis unknown\", \"Whether all Darier mutations act through haploinsufficiency vs. toxic gain-of-function unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Analysis of SERCA2+/− mice revealed compensatory remodeling—upregulation of PMCA isoforms, Na⁺/Ca²⁺ exchanger, and altered PLB phosphorylation—that partially buffers reduced pump activity, establishing the principle that cells adapt Ca²⁺-handling networks when SERCA2 is diminished.\",\n      \"evidence\": \"SERCA2 heterozygous knockout mice with confocal Ca²⁺ imaging, myocyte contractility, exocytosis assays, and synaptotagmin isoform Western blotting\",\n      \"pmids\": [\"10970890\", \"11387203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether compensatory mechanisms fail under chronic stress not tested\", \"Mechanisms triggering compensatory gene expression changes unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"SERCA2 haploinsufficiency was found to predispose to squamous cell tumors without loss of heterozygosity, establishing SERCA2 as a haploinsufficient tumor suppressor that alters epithelial tumorigenic potential through Ca²⁺ signaling perturbation.\",\n      \"evidence\": \"Aged Atp2a2+/− mice with histopathology; laser capture microdissection showing retained wild-type allele; ras mutation and p53 analysis\",\n      \"pmids\": [\"11389134\", \"16204033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream oncogenic pathways activated by partial SERCA2 loss not fully defined\", \"Whether tumor suppressor role extends to human epithelial cancers not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of Cys674 S-glutathiolation as a redox-sensitive activating switch resolved how NO signals through SERCA2 to relax arteries, and showed that irreversible Cys674 oxidation in atherosclerosis abolishes this regulation.\",\n      \"evidence\": \"Reconstituted purified SERCA2 in vesicles; C674S mutagenesis; mass spectrometry of oxidized Cys674 in atherosclerotic tissue\",\n      \"pmids\": [\"15489859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other Cys residues that may undergo regulatory oxidation not surveyed\", \"Whether Cys674 oxidation is reversible in early disease stages unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Calumenin was identified as a luminal SERCA2 inhibitor that binds the L4 loop (residues 853–892) preferentially in the E1 state, revealing that SERCA2 is regulated from both cytoplasmic and luminal sides.\",\n      \"evidence\": \"GST-pulldown domain mapping; oxalate-supported Ca²⁺ uptake assays; calumenin knockdown in HL-1 cells\",\n      \"pmids\": [\"19740751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological conditions that modulate calumenin–SERCA2 interaction not defined\", \"Whether calumenin and PLB regulation are synergistic or independent unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Two discoveries expanded the regulatory landscape: SUMOylation at K480/K585 was shown essential for SERCA2a stability and ATPase activity (reduced in heart failure, rescued by SUMO1 gene therapy), and Darier disease missense mutants were found to aggregate, trigger ER stress, and cause apoptosis, revealing a toxic gain-of-function mechanism beyond haploinsufficiency.\",\n      \"evidence\": \"Site-directed mutagenesis of K480/K585; AAV-SUMO1 delivery in pressure-overload mice; DD mutant expression in keratinocytes with solubility, ubiquitination, and ER stress assays\",\n      \"pmids\": [\"21900893\", \"22045735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SUMO E3 ligase responsible for SERCA2a SUMOylation not identified\", \"Which DD mutations act through aggregation vs. pure loss-of-function not systematically classified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"SERCA2b inhibition was shown to disrupt keratinocyte adhesion through sphingolipid pathway perturbation—increasing sphingosine and decreasing SPHK1—with rescue by sphingolipid lyase inhibition, providing a mechanistic link between ER Ca²⁺ depletion and Darier disease pathology.\",\n      \"evidence\": \"Thapsigargin and siRNA SERCA2b inhibition; sphingolipid analysis; rescue of E-cadherin and desmoplakin localization by sphingolipid lyase inhibitor\",\n      \"pmids\": [\"22277942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether sphingolipid pathway is perturbed in Darier patient skin not confirmed\", \"Direct Ca²⁺-sensing mechanism controlling SPHK1 expression unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"PDE3A1 was identified as a SERCA2 signalosome component: PKA-dependent phosphorylation of PDE3A1 at Ser292/293 promotes its incorporation into SERCA2/AKAP18 complexes, establishing a mechanism by which local cAMP pools control PLB phosphorylation and SERCA2 activity.\",\n      \"evidence\": \"Reciprocal co-IP of endogenous proteins from human SR; deletion mutant and mutagenesis mapping; gel filtration chromatography\",\n      \"pmids\": [\"25593322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PDE3A1 directly modulates SERCA2 activity independent of cAMP hydrolysis not tested at this time\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"SERCA2 was established as critical for pancreatic β-cell function: heterozygous loss impaired glucose-stimulated Ca²⁺ mobilization, insulin secretion, and β-cell mass under metabolic stress, and pharmacological SERCA2 activation rescued β-cell death.\",\n      \"evidence\": \"SERCA2+/− mice on high-fat diet; Ca²⁺ imaging in islets; insulin secretion assays; SERCA2 activator treatment\",\n      \"pmids\": [\"27489309\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific SERCA2 activator mechanism of action not characterized\", \"Whether SERCA2 dysfunction contributes to human type 2 diabetes not directly shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Multiple new regulatory modifications and downstream consequences were uncovered: JNK2 directly phosphorylates SERCA2 to increase Vmax; O-GlcNAcylation modulates β-cell insulin hypersecretion; TG2-mediated serotonylation inhibits SERCA2 promoting pulmonary vascular remodeling; and Cys674 inactivation activates calcineurin/NFAT signaling driving aneurysm and hypertension through ER stress pathways.\",\n      \"evidence\": \"Co-IP and ATPase assays (JNK2); OGT β-cell knockout with SERCA2 activation rescue; TG2 conditional knockout with hemodynamics; C674S knock-in mice with calcineurin, IRE1α, and renal pathway analyses\",\n      \"pmids\": [\"33334123\", \"32375037\", \"32116663\", \"32035136\", \"31758704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"JNK2 phosphorylation site on SERCA2 not mapped\", \"O-GlcNAcylation sites not identified by mutagenesis\", \"Serotonylation site not confirmed by mutagenesis\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The AKAP18δ scaffold was shown to bidirectionally regulate CaMKIIδ activity at SERCA2 through distinct N- and C-terminal domains, and brain-specific SERCA2 haploinsufficiency was found to produce a hyperdopaminergic phenotype with behavioral abnormalities, extending SERCA2 physiology to neuropsychiatric function.\",\n      \"evidence\": \"Peptide arrays, SPR, FRET-based CaMKII assays, AAV injection in mice (AKAP18δ); conditional brain Atp2a2+/− mice with in vivo microdialysis and behavioral testing\",\n      \"pmids\": [\"34814703\", \"34104969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SERCA2 haploinsufficiency leads specifically to dopamine elevation mechanistically unclear\", \"Whether AKAP18δ scaffold architecture differs between cardiac and neuronal SERCA2 pools unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Sigma-1 receptor was identified as a SERCA2 binding partner that promotes its ubiquitin-dependent degradation via Hrd1/Sel1L ERAD at K460/K541, and PDE3A was shown to directly inhibit SERCA2 through actuator domain binding (aa 169–216) independently of its catalytic activity, with disruptor peptides rescuing SERCA2 function in failing hearts.\",\n      \"evidence\": \"IP-MS; co-IP with mutagenesis of Q615, K460/K541 (Sigmar1-SERCA2); 2-color dSTORM, SPR, peptide arrays, and AAV9 disruptor peptide delivery reducing cardiac mortality (PDE3A-SERCA2)\",\n      \"pmids\": [\"35611810\", \"36876489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Sigmar1-mediated SERCA2 degradation is regulated by ligands in vivo unknown\", \"Structural basis of PDE3A actuator domain inhibition not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Ser663 was identified as a pathophysiological inhibitory phosphosite elevated in ischemic hearts, MFN2 was shown to enhance SERCA2 activity at MAMs for mitochondrial Ca²⁺ transfer in CD8⁺ T cells, and β-cell SERCA2 loss was found to mislocalize proinsulin processing enzymes, revealing new site-specific regulation, subcellular coupling, and organelle-level consequences of pump dysfunction.\",\n      \"evidence\": \"Phosphoproteomics of ischemic human hearts with S663 mutagenesis; MFN2-SERCA2 co-IP with conditional Mfn2 ablation in CD8⁺ T cells; β-cell SERCA2 knockout with proinsulin/proPC2 localization and RNA-seq\",\n      \"pmids\": [\"37291092\", \"37738362\", \"37537395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for Ser663 phosphorylation not identified\", \"Structural basis of MFN2-SERCA2 interaction at MAMs unknown\", \"Whether proinsulin trafficking defects occur in human SERCA2-deficient β-cells not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the identity of the kinase(s) phosphorylating Ser663, the specific O-GlcNAcylation and serotonylation sites on SERCA2, the structural basis of the PDE3A–actuator domain inhibitory interaction, and the mechanism by which partial SERCA2 loss selectively elevates dopamine in the brain.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ser663 kinase identity unknown\", \"O-GlcNAcylation and serotonylation sites unmapped by mutagenesis\", \"No high-resolution structure of SERCA2–PDE3A or SERCA2–AKAP18δ complexes\", \"Mechanism linking SERCA2 haploinsufficiency to dopaminergic hyperactivity unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 1, 4, 5, 14, 29]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 4, 5, 10, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 16, 26, 30]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 4, 5, 10, 14, 29]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [2, 5, 6, 17, 24, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 16, 22, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 7, 8, 15, 25]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [14, 26]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [28]}\n    ],\n    \"complexes\": [\n      \"SERCA2/PLB complex\",\n      \"SERCA2/AKAP18δ/CaMKIIδ signalosome\",\n      \"SERCA2/PDE3A1/AKAP18 signalosome\"\n    ],\n    \"partners\": [\n      \"PLN\",\n      \"PDE3A\",\n      \"AKAP18\",\n      \"CAMK2D\",\n      \"SIGMAR1\",\n      \"MFN2\",\n      \"CALU\",\n      \"MAPK9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}